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Abstract 
Prolonged exposure to opioids results in analgesic tolerance, drug overdose, and death. 
The mechanism underlying morphine analgesic tolerance still remains unresolved. 
Currently, there are studies focusing on the role of the gut microbiota and its 
interactions with gut and brain (the microbiota-gut-brain axis) in substance abuse, 
especially opioid abuse. The microbiota-gut-brain axis is a bidirectional 
communication between central nervous system and gastrointestinal system. Emerging 
literature provides evidence that the gut microbiota orchestrates neurogenesis, brain 
development and function, as well as blood-brain-barrier integrity, and host behavior 
through vagal afferents, gut hormones, cytokines, and microbial metabolites. Gut 
dysbiosis disrupts the homeostasis between brain and gut in neurodegenerative disorder, 
central nervous system injury, and exacerbates disease progression. In opioid abuse 
subjects, increased comorbidity and behavioral changes are found to be associated with 
impaired gut integrity and bacterial translocation. We show that morphine analgesic 
tolerance was significantly attenuated in germ-free (GF) and in pan-antibiotic-treated 
(ABX) mice. Reconstitution of GF mice with naïve fecal microbiota reinstated 
morphine analgesic tolerance. We further demonstrated that tolerance was associated 
with microbial dysbiosis with selective depletion in Bifidobacteria and Lactobacillaeae. 
Probiotics, enriched with these bacteria, attenuated analgesic tolerance in morphine-
treated mice. These results suggest that probiotics therapy during morphine 
administration may be a promising, safe, and inexpensive treatment to prolong 
morphine’s efficacy and attenuate analgesic tolerance. We hypothesize a vicious cycle 
of chronic morphine tolerance: morphine-induced gut dysbiosis leads to gut barrier 
disruption and bacterial translocation, initiating local gut inflammation through TLR2/4 
activation, resulting in the activation of pro-inflammatory cytokines, which drives 
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morphine tolerance.  
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CHAPTER 1 
BACKGROUND-LITURATURE REVIEW  
1. GUT-BRAIN AXIS 
A. Concepts of gut-brain axis 
The gut-brain axis is a bi-directional neuro-humoral communication system that links 
gut and brain function (emotional and cognitive centers)(1). The axis involves neural, 
endocrine and immunological signaling, vagus nerve, and microbial metabolites to 
integrate the two organs(2). The microbiota has functioned as a key player in the control 
of this axis. The gut microbiota is an ecological community of trillions of commensal, 
symbiotic and pathogenic microorganisms, including bacteria, archaea, yeast, helminth, 
parasites, virus, and protozoa(3). The Human Microbiome Project reveals distinct gut 
microbiome in health and disease. Gram-positive Firmicutes, gram-negative 
Bacteroidetes, are the dominant phyla that inhabit the human gut. Actinobacteria, 
Fusobacteria, Proteobacteria and Verrucomicrobiota are present at subdominant 
levels(4). This complex and dynamic bidirectional relationship of host v.s. microbiota 
is fragile (symbiosis) and can be easily disrupted. When the balance is disturbed, the 
beneficial and dominating species are underrepresented or outcompeted by hazardous 
species (dysbiosis)(5). The microbiota serves many important functions. It confers food 
digestion, regulating gut motility, intestinal barrier homeostasis, nutrient absorption, 
and immune system development, maturation and defense, fat distribution, essential 
vitamins and amino acids synthesis(2)(6).  
 
B. The gut microbiota is related to human health 
Microbiota and their host organisms are mutually co-dependent for survival. 
Microbiota has been linked with different organs and tissues in the host, including liver, 
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intestine, cardiovascular, lung, brain, bone and adipose tissue(1). Dysbiosis is 
associated with various diseases by affecting microbial composition, diversity and 
metabolites, such as NAFLD/NASH (Non-alcoholic fatty liver disease/ Nonalcoholic 
steatohepatitis) in liver, inflammatory bowel disease (IBD)/ Crohn’s disease in intestine, 
heart failure, allergic asthma in lung, autism spectrum disorder, stress and stroke in 
brain, obesity and Type 2 diabetes, systemic lupus erythematosus, atherosclerosis as 
autoimmune disease(7)(8)(9)(10)(11)(12)(13)(14)(15) (Fig. 1.1).   
 
The gut microbiota is influenced by many aspects: mechanical bowel cleaning, 
antibiotics, stress-released hormones (catecholamines), vasoactive drugs 
(norepinephrine), endogenous and exogenous opioids (morphine), enteral feeding 
restriction, micronutrients insufficiency, operation/ gut manipulation/ resection/ 
anastomosis, probiotics (which contain live beneficial bacteria), prebiotics (which 
contain supplements that promote the growth of specific bacteria), neonatal mode of 
delivery, breast feeding, environmental exposures early in life(16).  
 
C. Various communication pathways in gut-brain axis 
There is increasing evidence that gut microbiota is implicated in the neural system 
development and neurodegenerative disease(17)(18)(19). Studies comparing GF mice 
and ABX-treated mice with conventionally raised controls elucidate the role of the gut 
microbiota in nervous system development and function(20). The majority of gut-brain 
communication is being facilitated via 4 distinct routes: 1) microbial metabolites; 2) 
cytokines; 3) vagus afferent; and 4) gut hormones(21) (Fig. 1.2). 
 
1) Microbial metabolites 
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Gut microbiota produces bioactive molecules, such as SCFA, niacin, urolithins, equol, 
indole, protocatechuic acid, and 8-prenylnaringenin, that interact with host. Microbiota 
also stimulates the synthesis and release of neurotransmitters, GABA, acetylcholine, 
norepinephrine, dopamine, and serotonin(22). These various metabolites cross the 
intestinal barrier and flow into the circulatory system. They cross the blood brain barrier 
(BBB) to modulate neurological functions and behaviors. Using capillary 
electrophoresis mass spectrometry with time-of-flight (CE-TOFMS), different 
intestinal metabolic profile between GF mice and GF mice transplanted with SPF 
mouse microbiota was identified(23). The GF mice have reduced levels of metabolites 
associated with energy metabolism such as pyruvic acid, citric acid, fumaric acid, and 
malic acid(24). However, GF mice have elevated noradrenaline, dopamine and 5-HT 
turnover in the striatum compared to SPF mice, accordingly displaying increased motor 
activity and decreased anxiety(25). Therefore, a comprehensive understanding of 
microbiota metabolites is critical for clarifying the microbiota-host interactions.  
 
Recent studies investigated the potential of bacterial metabolites to drive host 
phenotypes and disease outcomes. The levels of 5-HT (serotonin) are found to be 
significantly lower in the GF mice. However, the administration of Lactobacillus 
plantarum PS128 significantly increased serotonin level in the striatum, thus relieving 
animal’s early life stress(26). Bifidobacterium infantis has antidepressant properties in 
rats through changes in the tryptophan/kynurenine pathway(27). It indicates the 
microbial metabolites from probiotics could improve anxiety-like behaviors. The 
prebiotics administration altered the mouse gut microbiota, relieved chronic 
psychosocial stress by increasing acetate and propionate and decreasing butyrate(28). 
These above examples indicate the constant, life-long interaction of gut microbiota and 
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human host, which influence neurological function and behavior during development 
or within health and disease states.  
 
2) Cytokines and regulation of immune cells 
Gut microbiota contribute to behavior changes via induction of cytokine secretion. 
During bacteria or virus infection, the immune system is activated and induces the 
production of pro-inflammatory cytokines. The cytokines, generally hydrophilic, cross 
the BBB and deposit into the CNS, leading to a sickness reaction characterized by 
behavioral symptoms such as fatigue, lassitude, inability to concentrate, irritability, loss 
of appetite and withdrawal from social interactions(29). In the VPA-induced autism 
spectrum disorder (ASD) mouse model, the microbial composition was shown to be 
altered, with increased neutrophil infiltration and intestinal inflammation(30). There is 
converging evidence showing dysbiosis contributing to an exacerbated 
neuroinflammatory status leading to dysfunction of brain areas related with mood 
regulation, learning, and memory. For instance, in non-celiac gluten sensitivity (NCGS), 
a chronic functional gastrointestinal disorder, gut dysbiosis induces gut inflammation, 
and abdominal pain. The LPS from pathogenic bacteria activates the systemic 
inflammation and oxidative stress, and ultimately triggers neuroinflammation and 
promotes NCGS-induced dementia(31). These studies indicate dysbiosis are crucial 
drivers of neuropsychiatric complications.  
 
Experimental autoimmune encephalomyelitis (EAE) is attenuated in GF mice with 
lower levels of proinflammatory cytokines IFN-g and IL-17A in spinal cord but higher 
number of CD4+CD25+Foxp3+ regulatory T cells. In addition, GF animals failed to 
stimulate proinflammatory T cell responses. However, GF animals with Segmented 
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Filamentous Bacteria (SFB) supplement showed EAE development and 
neuroinflammation(32)(33). Additionally, in the mouse model of middle cerebral artery 
occlusion (MCAO)-induced ischemic brain injury, mice with the antibiotics 
amoxicillin and clavulanic acid resistant bacteria (dysbiosis) induced intestinal DCs 
priming, leading to the expansion of local IL-10 secreting- Treg cells in the small 
intestine and suppression of effector IL-17+ gd T cell function. Less effector T cells 
traffic from gut to meninges, thus decreasing post-ischemic chemokine (CXCL1 and 
CXCL2) expression and leukocyte infiltration, reduced infarct volume and thus 
improving sensorimotor function(34). FMT of brain-injured animals developed 
significantly larger infarct volumes after cortical lesions in the MCAO stroke model 
compared with controls that recolonized with sham-surgery microbiota. However, 
restoring healthy microbiota daily in experimental animals reduced the lesion after 
large stroke with increased number of Foxp3+ Treg cells(35). While the role of 
microbiome in influencing CNS immunologic activities is well established, better 
insight can be gained by identifying the particular bacteria that are associated with 
behavior such that treatment strategies can be developed.   
 
3) Gut hormones 
Gut hormones, in addition to neuropeptides, secreted by enteroendocrine cells in 
gastrointestinal tract, are found to play a role of neuromodulators in the central and 
peripheral nervous systems. NPY (neuropeptide Y) regulates cognitive processes. In 
both GF and antibiotics cocktail mouse models, NPY mRNA expression are 
prominently increased, and the novel object recognition memory is compromised in 
these antibiotic-treated mice(36).  
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Autoantibodies (autoAbs) against appetite-regulating peptides are associated with 
eating disorders. The National Center for Biotechnology Information (NCBI) database 
showed that pathogenic micro-organisms such as E.coli strains, Helicobacter pylori, 
Clostridium tetani, human immunodeficiency virus type 1, C. albicans, A. fumingatus, 
and C.neoformans displayed a sequence homology of a-MSH. The results imply that 
autoAbs cross-react with these bacterial components and trigger the eating disorders. 
Levels of IgA autoAbs against appetite-regulating peptides agouti-related protein, 
melanin-concentrating hormone, corticotropin-releasing hormone were found 
decreased in GF rats compared with conventionally raised controls, while the levels of 
antighrelin IgG were increased. It indicated that the gut microflora control appetite 
indirectly by regulating the formation of autoantibodies against neuropeptides/peptides 
involved in this process(37). 
 
4) Vagal 
The vagal afferent pathway has emerged as an important means of communicating 
signals from gut to CNS. Gut microbiota is a source of various biologically active 
peptides and mediators such as GABA, serotonin, norepinephrine, melatonin, histamine, 
and acetylcholine(38)(39). Specific bacterial communities have been found to be 
associated with neurotransmitter synthesis or metabolism. For example, Lactobacillus 
spp. and Bifidobacterium spp. produce GABA; Escherichia spp., Bacillus spp. and 
Saccharomyces spp. produce noradrenalin; Candida spp., Streptococcus spp., 
Escherichia spp. and Enterococcus spp. produce serotonin; Bacillus spp. produce 
dopamine; and Lactobacillus spp. produce acetylcholine(40). These neurotransmitters 
and neuromodulators are released into the blood circulation, cross the BBB and act on 
vagus nerve to regulate host behavior. For example, acetylcholine release from vagus 
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nerve plays an immunosuppressive role in inhibiting the release of macrophage TNF-
a and attenuating systemic inflammatory responses by binding to acetylcholine-
receptor a7 subunit(41).  
  
The presence of certain bacteria in the gastrointestinal tract have an impact on brain 
function and behavior. For example, mice challenged with subclinical dose of pathogen 
Campylobacter jejuni (C. jejuni) exhibited anxiety-like behavior by reducing 
exploration in open arms of the plus maze(42). Brain activation is observed in the 
nucleus tractus solitarius (NTS), which is the first entrance of vagal afferents in the 
brain, indicating the vagus nerve involvement. Similarly, GABA, as main CNS 
inhibitory neurotransmitter, its concentration and GABA receptor expression are 
involved in pathogenesis of depression and anxiety. Chronic administration with L. 
rhamnosus induced region-dependent alterations in GABA(B1b) and GABA(Aα2) 
mRNA in certain brain regions. Thus, L. rhamnosus reduced stress-induced 
corticosterone concentration in plasma and depression- and anxiety-related behavior. 
However, the effects of L. rhamnosus on neurotransmitter and behavioral effects were 
not found in subdiaphragmatically vagotomized mice(43). The anxiolytic effect of 
Bifidobacterium longum NCC3001 on chronic colitis induced anxiety-like behavior 
was dependent on vagus integrity(44). These studies implicate the vagus system as one 
of the major communication pathways between gut and brain. 
 
D. Research tools in gut microbiota studies 
In research, gnotobiotic animal models were developed to decipher the gut microbiome. 
Germ-free (GF) animals are powerful tool to demonstrate direct involvement of 
components of the gut microbiota in human health and diseases. GF animals selectively 
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colonized with one or more bacterial species allow researchers to study their effects 
isolated from other microbes. The fecal microbiota transplantation (FMT) from 
human patients into GF mice allow investigators to determine whether dysbiosis 
associated with a disease is a cause, a contributing factor, or a consequence of the 
disease state. However, GF mice have numerous immune abnormalities, including 
underdeveloped lymphoid follicles, fewer and smaller Peyer's patches and mesenteric 
lymph nodes, defects in antibody production, diminished numbers of T cells and B cells 
and deficits in cytokine production(45). Therefore, antibiotics-treated mice become an 
alternative choice. Antibiotics-treated animals are used to investigate effects of 
disrupting the microbiome in specific life stages of the host and effects of targeting 
certain groups of bacteria (Gram-positive or Gram-negative).  
 
2. GUT-BRAIN AXIS IN OPIOIDS ABUSE 
A. Opioid tolerant patients are at higher risk of sepsis and complications due 
to morphine’s deleterious effects on gut. 
Chronic opioid consumption has a lot of deleterious effects. It is associated with higher 
risk of coronary artery disease, bladder cancer, liver cirrhosis, deep vein thrombosis, 
asthma and chronic obstructive pulmonary disease(46)(47)(48)(49)(50)(51). Opioid 
use is also found to associate with a higher risk of gastrointestinal mortalities such as 
esophageal cancer in a dose dependent manner(52). In opioid users, the increased 
morbidity was driven largely by infectious complications (surgical site infection, 
specifically superficial surgical site infection, pneumonia and sepsis)(53)(54)(55). 
Therefore, opioid users, especially opioid tolerant patients had a significantly longer 
length of hospital stay and a greater all-cause hospital readmission rate than the non-
opioid users(55). As a result, the opioid tolerant population is at risk given the poorer 
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outcomes and higher health care costs associated with their care(56). One of the 
explanations is that morphine is associated with impaired bacterial clearance and 
enhanced susceptibility to infectious organisms(57). Higher circulating morphine levels 
are observed in patients with sepsis, severe sepsis and septic shock(55). Morphine 
treatment is suspected to serve as a cofactor in the precipitation of complications by 
impairing gut barrier integrity, which allows bacterial translocation from the gut lumen 
into the peritoneal organs and circulatory system(58)(59).  
 
Among all septic patients, both gram-positive and gram-negative bacterial infections 
were common in opioid-treated patients(55). Fungal infection was more prevalent in 
opioid-treated patients compared with non-opioid-treated patients as well(55). The 
most prevalent gram-positive bacteria were Staphylococcus, Streptococcus, and 
Enterococcus and the most prevalent gram-negative bacteria were Escherichia coli, 
Salmonella, and Campylobacter(58)(60). Candida albicans was the most prevalent 
fungus(61). In mice, morphine enhanced Proteus Mirabilis, gram-negative bacteria, 
translocation to liver, spleen and peritoneal cavity(62). Previous data in our lab showed 
that gram-positive bacteria such as Enterococcus sp., Staphylococcus sp., and Bacillus 
sp. disseminated into MLN, spleen and liver, therefore exacerbating sepsis in a mouse 
cecal ligation and puncture (CLP) model(58). These findings implicated that morphine-
induced expansion of gram-positive bacteria and gram-positive bacterial dissemination 
inhibits bacterial clearance.  
 
B. Morphine induces gut dysbiosis and enhances the virulence of pathobiome.  
We further unraveled that morphine induced a global change in the gut microbiota. A 
significant shift in gut microbial composition was observed in morphine-treated 
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animals with a preferential expansion of Enterococcaceae, Staphylococcaceae, 
Bacillaceae, Streptococcaceae and Erysipelotrichaceae(60). It implies that the poorer 
outcomes from opioid-using patients were due to gut microbiota shift to more 
pathogenic strain. Moreover, comparing intermittent morphine injection with 
continuous morphine pellet, the intermittent injection model exhibited a more distinct 
microbial profile with decreased beneficial communities Lactobacillus and an 
expansion of more pathogenic strains such as Ruminococcus(63).  
 
Recent studies of C. Acharya found that chronic opioids (most case oxycodone) 
exhibited a different microbiota profile compared to non-opioid hepatic encephalopathy 
(HE) patients. Autochthonous taxa (Lachnospiraceae, Ruminococcaceae, and 
Clostridiales XIV) were significantly decreased in HE patients on opioids while 
Bifidobacterium was higher. In no-HE patients, opioids use caused decreased 
Parasutterella abundance while increased Peptostreptococcaceae abundance. The 
lower abundance of autochthonous bacteria and Bacteroidaceae was correlated with 
outgrowth of potentially harmful pathogens and longer hospitalizations. The PiCRUST 
(Phylogenetic Investigation of Communities by Reconstruction of Unobserved States) 
functional metagenomics analysis predicted that opioids-induced microbiota alteration 
associated with the functions related to metabolism of aromatic amino acids and 
degradation of potentially beneficial branched-chain amino acids while gut microbiota 
related to branched-chain amino acid synthesis and bioenergetics processes were more 
abundant in non-opioid users. In HE patients on opioids, gut microbiota were associated 
with endotoxin and endotoxin protein synthesis, nitrogen metabolism, motility and 
degradation of the branched-chain amino acids compared to those with non-opioids HE 
patients. These opioids-induced dysbiosis partially explained increased IL-6 in serum, 
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worsened endotoxemia, leading to higher all-cause readmissions in patients with 
cirrhosis(64).  
 
Additionally, detailed research by John C. Alverdy group showed that opioid (U50,488, 
a highly selective kappa opioid) increased the virulence of bacteria in critical ill patients. 
These studies revealed a significant decrease in bacterial diversity with a predominant 
abundance of Enterococcus, Staphylococcus, and Enterobacteriaceae and an absence 
of Bacteroidetes in critical ill patients on opioids. In this study, C. elegans was used to 
evaluate survival rate and to test the virulence potential of the bacterial community. 
When exposure to opioids (50uM of U-50, 488), the bacterial community shifted to a 
pathogenic phenotype via quorum-sensing signaling systems, thus C. elegans survival 
rate decreased. It is hypothesized that opioids create a stress environment derivative of 
extracellular phosphate; thus, virulence expression of bacteria is enhanced. 
Supplementation with Pi-PEG15-20 was protective in opioid treated subjects(65).  
 
Although the mechanisms of morphine-induced gut dysbiosis are elusive, we speculate 
that morphine abuse and withdrawal commonly cause disruption of neurotransmission 
in enteric nervous system, gut motility, mucosal immunity, secretion of water, 
electrolytes, and bile acids in the gastrointestinal tract, resulting in constipation or 
diarrhea(66)(67). These may contribute to morphine-induced dysbiosis.  
 
C. The mechanisms how gut microbiome affects opioids-induced behavior 
changes. 
The role of the microbiome in opioid-associated behavioral outcomes was tested in 
several studies using the antibiotic depletion strategy. Gut flora depletion prevented 
chronic morphine-induced analgesic tolerance by preserving gut integrity, stopping 
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colonic mucosal disruption, and down-regulating colonic IL-1β expression. It was 
found that inactivation of tetrodotoxin-resistant (TTX-R) Na+ channel in nociceptive 
primary afferent neurons was mitigated when exposed to morphine-tolerant mice 
colonic supernatant. However, it was prevented by oral vancomycin. These studies 
indicated that bacterial products, proinflammatory cytokines and other components 
produced as a consequence of morphine-induced dysbiosis provide an environment for 
inhibition of TTX-R Na+ channels inactivation in dorsal root ganglions, which explains 
the attenuation of morphine tolerance in bacteria depleted condition(68)(69).  
 
Data from our laboratory identified Enterococcus faecalis (E. faecalis) as a biomarker 
of morphine induced dysbiosis. Gavage of E. faecalis into mice exacerbated morphine 
analgesic tolerance(69).  
 
In a more recent study, using antibiotic depletion strategy, mice with depleted 
microbiota showed no preference for either the cocaine- or saline- paired chamber in 
conditioned place preference study. It indicated gut microbiota participate in cocaine 
reward behavior. Additionally, mice with FMT from morphine-treated donors had 
increased microglial cell body size and activated microglia in both the midbrain and 
dorsal horn of the spinal cord compared to FMT from saline microbiota transplant. Thus, 
FMT from morphine-treated mouse disrupted cocaine rewarding pathway(70). 
Manipulation of gut microbiome without direct exposure to morphine also had an 
influence on neuroinflammation and opioid-dependent behavior.  
 
To investigate if a specific bacterial profile can serve as biomarker of addiction, Xu et 
al demonstrated that addiction (heroin, crystal methamphetamine, ephedrine, heroin + 
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ephedrine and heroin + crystal methamphetamine) was associated with a significant 
increase in Thauera, Paracoccus and Prevotella bacterial communities. In addition, 
functional metagenomics analysis using PiCRUST analysis indicated that these 
bacterial communities were associated with functions such as translation, DNA 
replication and repair, and cell growth and death were up-regulated in gut microbiota 
of substance use disorder subjects. The over-represented pathway might explain the 
substance induced- dysbiosis exerts functional effects on cell communication, 
cardiovascular diseases, and circulatory system(71). 
 
Studies have shown that the dynamic interplay between morphine pharmacokinetics 
and bile acids concentration. Recent studies from Wang et al. show that morphine 
disrupted bile acid metabolomics profile. The concentration of cholic acid, deoxycholic 
acid, chenodeoxycholic acid, keto-deoxycholic acid, muricholic acid haven been found 
decreased in mouse fecal matter after morphine treatment for 3 days(60). 
Simultaneously, morphine metabolism is also regulated by liver function. In patients 
who have impaired liver function such as in nonalcoholic steatohepatitis (NASH), the 
concentration of morphine-6-glucuronide (M-6G) and morphine-3-glucuronide (M-3G) 
were higher compared to healthy controls(72). It implicates that accumulating M-3G 
and lower concentration of bile acids provide a deleterious environment for 
Bacteroidales communities such as Bifidobacteria to survive in the gut. Strict 
anaerobes such as Bacteroides and Bifidobacteria produce β-glucuronidase, which 
exert an essential role in morphine metabolism. They hydrolyze M6G and M3G, 
allowing them to be reabsorbed as morphine. Morphine treatment reduced abundance 
of Bacteroidales communities, thus less morphine circulates back into system resulting 
in escalating morphine consumption, indicating the generation of analgesic tolerance.  
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These recent observations have indicated that indigenous bacteria do indeed alter 
aspects of their hosts’ neurological function, leading to effects on morphine-induced 
behavior changes, including tolerance, rewarding, and addition. However, the precise 
mechanisms of how the gastrointestinal microbiota have an effect on neurological 
function and behavior remain largely unexploited but are likely complicated and varied.  
 
3. POTENTIAL MECHANISMS OF MORPHINE TOLERANCE  
US Food and Drug Administration defined opioid tolerance as the use of greater than 
or equal to 60 mg of oral morphine equivalents (30 mg of oral oxycodone) daily for 7 
days or longer, regardless of long-term opioid use(73). Acute opioid tolerance may 
develop quickly in opioid-naive patients, leading to higher opioid doses and increased 
risk of opioid-related overdose death(74). The burden of substance abuse is actually 
growing, due in part to an alarming increase in the rate of opioid abuse. It has been 
estimated by NIDA that substance abuse costs $600 billion annually in the U.S., 
including loss of productivity, healthcare spending, and increase of criminal activities. 
The rate of deaths from drug overdoses has risen 2-fold from 2002 to 2017. Standard 
medical therapy including psychotherapy, behavior modification and pharmacotherapy 
is often not curative, and relapse is common. It is urgent to explore the mechanisms 
underlying morphine tolerance and to develop potential therapies. Several mechanisms 
are outlined below. 
 
A. Neuroinflammation contributes to morphine analgesic tolerance  
Microglia cells and astrocyte are immune cells in the central nervous system. Chronic 
morphine administration induces these non-neuronal immunocompetent cells to secrete 
cytokines such as TNFα, IL-1β, IL-6, CCL2 and CX3CL1(75)(76). These cytokines act 
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on both glia cells and the pre- or post-synaptic neurons. On microglia cells, the 
expression of purinergic receptor P2X purinoceptor (P2X7R) and P2X4R, and Toll-like 
receptor 4 (TLR4) were up-regulated following chronic morphine treatment(77)(78). 
Concomitantly, at the presynaptic level, chronic morphine treatment enhances 
excitatory synaptic transmission by release of chemokines, substance P (SP), glutamate 
and calcitonin gene-related peptide (CGRP)(79). The chronic morphine treatment plus 
the pro-inflammatory environment activate N-methyl-D-aspartate receptor (NMDAR).  
The activation of the NMDAR on neuron promotes neurotoxicity and neuron apoptosis 
through regulating inhibitory neuron transmitter GABA transmission(79). Together, 
the interaction between neurons and immune cells promotes further neuroimmune 
activation, enhances neuronal sensitization, and exacerbates OPRM signaling thus 
impacting morphine analgesic tolerance.  
 
The functions of different cytokines, chemokines, innate immune pattern recognition 
systems are well-characterized in triggering and maintaining morphine tolerance. 
Blockade of the formation or activation of proinflammatory cytokines such as IL-6, IL-
1b, TNFa, or CX3CL1 attenuates the development of tolerance(80). Morphine 
tolerance was alleviated by minocycline and CXCR3 inhibitor through blocking the 
interaction of neuron-microglia(81). CXCL12 neutralizing antibody and AMD3100 
(CXCR4 antagonist) preserved morphine analgesic efficacy. Administration of 
cytokines such as CXCL12 accelerates morphine tolerance(82). Blockade of 
complimentary factor 5 receptor (C5aR) or tissue plasminogen activator (tPA) or 
neuronal matrix metalloproteinase 9, or neuronal nitric oxide synthase restored 
morphine antinociception and inhibited the development of morphine 
tolerance(83)(84)(85)(86). Anti-inflammatory treatment such as recombinant rat IL-
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10 (rrIL-10) and ibudilast, glial cell metabolic inhibitor propentofylline and 
pentoxifylline, astrocyte activity inhibitor fluorocitrate attenuated the development of 
morphine tolerance(87)(88)(89)(90). However, the precise mechanisms how 
neuroinflammation interacts with neuron cells and drives morphine tolerance are not 
delineated.  
 
B. The role of TLR4 and TLR2 in morphine tolerance 
The TLR4 signaling pathway is an important contributor to the development of 
tolerance following continued exposure to opioids. Morphine-3-glucuronide (M3G), 
one of the major metabolites of morphine, activates TLR4, causes subsequent 
microglial proinflammatory activation and releases IL-1β. Moreover, TLR4/MD2 
complex, followed by MyD88 pathway, drives morphine-induced proinflammatory 
cytokines IL-1β and TNF-α(91).  
 
Furthermore, ATP-sensitive potassium channel regulates HSP70 release by neuron 
cells. The HSP70 activates TLR4 signaling pathway on microglia, induces NLRP3 
inflammasome activation, and promotes the formation of mature IL-1β by activating 
caspase-1, thus contributing to morphine tolerance(92). As a result, morphine tolerance 
was observed to attenuate both in TLR4KO mice and following administration of KAPT 
blocker, glibenclamide(92).  
 
However, the role of TLR4 signaling pathways in morphine analgesia is controversial. 
Wang et al. showed that both TLR4KO and MyD88KO (the critical downstream 
component) mice exhibited potentiated acute morphine analgesia(93). However, in a 
separate study, in contrast to the above described studies, Liu et al. showed that only 
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TLR4KO mice, but not MyD88KO mice, have an protective effect on chronic morphine 
tolerance(94). It implies that MyD88 dependent pathway participates in the generation 
and maintenance of acute not chronic morphine tolerance. However, due to limited 
studies, the role of MyD88 in chronic morphine tolerance needs to be further 
investigated.   
 
The interaction between OPRM1 and TLR2/4 signaling pathways remains to be 
elucidated. TLR2 and TLR4 are involved in pain hypersensitivity and morphine 
tolerance. For instance, HKLM (TLR2 agonist) induced- lasting tactile allodynia in WT 
mice was prevented in TLR2KO mice(95). In addition, primary glial cells from 
TLR2KO mice could not be activated as WT mice by damaged sensory neuron. Thus, 
the increased sensitivity to both mechanical and thermal stimuli observed in WT mice 
was attenuated in TLR2KO mice. Therefore, TLR2 is essential to produce pain-
mediating pro-inflammatory cytokines for nerve injury-induced spinal cord glial cell 
activation(96). Moreover, microglia in NAc had a higher expression of TLR2 after 
chronic morphine treatment. Morphine-induced microglia activation and 
proinflammatory cytokines were markedly inhibited in the TLR2KO mice. Therefore, 
the behavioral signs of morphine withdrawal were attenuated in TLR2KO mice, which 
indicates that TLR2 plays an important role in response to morphine dependence(97). 
In vitro study indicated that overexpression of TLR2 in HEK293 cells caused cell 
apoptosis after morphine treatment. However, blockage of TLR2 downstream target 
MyD88 or blockage of OPRM downstream β-arrestin 2 attenuated morphine-induced 
cell death(98). In addition, chronic morphine treatment induced decrease of anti-
apoptotic Bcl-2 gene expression and increase of pro-apoptotic Bax gene expression in 
cortex and lumbar spinal cord. Donepezil attenuated morphine-induced tolerance by 
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suppressing morphine-induced TLR2 and TLR4 expression up-regulation(99). 
Although there is limited report of the critical role of TLR2 in morphine tolerance 
currently, inhibition of TLR2 may find application in the development of novel 
therapies to treat opioid tolerance, dependence and addiction. 
 
C. Signaling pathways in morphine tolerance  
Acute morphine administration activates opioid receptors. Dissociation of Gi/o from 
OPRM inhibits the activity of adenylyl cyclase (AC) of cAMP signaling, augments K+ 
conductance and inhibits voltage gated Ca2+ channel function, which subsequently 
inhibits synaptic activity by suppressing the release of the excitatory neurotransmitters 
such as acetylcholine, serotonin, nitric oxide and intestinal peptide(100). However, 
tolerance development can be due to opioid-receptor changes (decreased activation, 
receptor desensitization and endocytosis) that occur after prolonged exposure to opioids. 
Chronic morphine treatment mediates G protein coupling by MOR switching from Gi/o 
to Gs protein and stimulates adenylyl cyclase II and IV by Gβγ dimer. Opioid tolerance 
activates the intracellular cAMP signaling pathway. The increase in cAMP levels 
results in the activation of cAMP-dependent protein kinase (PKA). Morphine-induced 
changes further lead to the activation of transcriptional factor Ca2+/cAMP response 
element binding protein (CREB), which may be important to the development of 
tolerance. The activation of Gi/o βγ subunit induces inositol lipid hydrolysis and 
produces IP3 and diacylglycerol (DAG), which consequently lead to release stores of 
intracellular Ca2+. It further activates the mitogen-activated protein (MAP) kinase, PKA 
and PKC(101)(102). Activated opioid receptor is phosphorylated by a G protein 
coupled receptor kinase (GRK), which recruits β-arrestin complex. The activated 
opioid receptor is desensitized and internalized. It is either recycled to the cell surface 
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or targeted for lysosomal degradation. Although chronic morphine treatment does not 
cause opioid receptor internalization(103), tolerance was attenuated by intrathecal β-
arrestin 2 small interfering RNA in rats(45). Additionally, one study has shown that 
morphine-induced OPRM internalization was detected in the presence of an inhibitor 
of conventional PKC isoforms(104). There is another study implying that PKC-
mediated desensitization of OPRM, suppressing cAMP-inhibition, thus exacerbating 
morphine tolerance(105). Additionally, intrathecal injection of siRNA against PKA 
blocked morphine tolerance by inhibiting morphine augmentation on calcitonin gene 
related peptide (CGRP) synthesis and release in primary sensory neurons(106). These 
studies help us gain insight into the mechanisms how interaction of different signaling 
pathways plays a key role in morphine tolerance. However, there is still no clear 
consensus on how chronic opioid use leads to analgesic tolerance. 
 
D. Role of Blood-Brain-Barrier in morphine tolerance.   
On the blood-brain-barrier (BBB), several ATP-binding cassette (ABC) transporters 
participate in the efflux of xenobiotics such as opioids from the CNS into bloodstream. 
It controls the brain concentration of the drugs and their effects on CNS and is 
responsible for the efflux of opioids. Chronic morphine treatment in rats has shown to 
have increased expression of P-glycoprotein (P-gp), thus implicating it in morphine 
tolerance. It has been reported that high level of glutamate induced by morphine 
tolerance activates NMDA receptor to up-regulate P-gp through COX-2. Another study 
demonstrated that chronic morphine exposure activates TLR4 with subsequent release 
of TNFα. TNFα binds to its receptors on endothelial cells and up-regulates P-gp 
expression through NF-kB(107).  
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However, whether chronic morphine modulates BBB integrity is controversial. Oishi 
et al. mentioned acute morphine resulted in increased brain permeability to sodium 
fluorescein in mice through activation of H2-receptors by neuronal histamine and 
muscarinic receptor by acetylcholine(108). Another study indicated that morphine 
withdrawal not morphine tolerance resulted in damage of BBB integrity. Microglia 
cells, which were activated by morphine withdrawal, mediated oxidative stress 
response and promoted BBB permeability(109).  
 
4. SUMMARY 
As delineated above, growing evidence from animals and human studies has shown that 
opioids can have a major impact on composition and function of gut microbiota. What 
is most intriguing from a treatment perspective is that modification of gut bacteria 
(antibiotics and FMT) can reverse the abnormalities of behavior changes related with 
substance abuse. It implies that opioid abuse-induced dysbiosis influences 
psychopathology by affecting gut permeability, microbial metabolites concentration, 
local inflammation and neuroinflammation, the related receptor expression and 
activation in CNS, and drug pharmacokinetics. The gut microbiota manipulation 
(prebiotics, probiotics, antibiotics, FMT) hold the greatest promise for novel treatments 
for opioids abuse. Basic research clinical trials are required to examine what is more 
efficacious to yield new insights into the role of gut-brain axis in opioid abuse. 
Although the microbiota-gut-brain axis is attractive in the field of substance abuse, this 
research is still in its infancy.  
 
Morphine tolerance may be multifactorial involving interaction between neurons, non-
neuronal immune cells and endothelial cells, neuroinflammation, activation of TLR and 
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alteration of OPRM1 signaling pathway (Fig 1.3). Although it has been well 
demonstrated that morphine treatment results in gut dysbiosis, impaired gut barrier 
integrity and bacterial translocation, it is unclear how morphine-induced gut 
pathologies exert influence on neuroinflammation and related behavior changes. We 
hypothesize that chronic morphine treatment induces dysbiosis and triggers gut 
inflammation. The cytokines generate from local inflammation cross BBB and mediate 
their effects directly in the CNS, which in turn modulate analgesic tolerance.  
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Figure 1.1 Gut microbiota and host have a bi-directional communication. The host diet, 
medication and living habits are associated with microbiota composition and diversity. 
The gut microbiota transform dietary molecules and environmental factors into 
metabolites and signaling molecules to regulate the host’s health. The gut microbiota 
plays a key role in various diseases. It affects different organs in human body as 
indicated above. 
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Figure 1.2 Interactions between the gut microbiota, peripheral system and CNS are 
essential for the maintenance of host health. The microbial-derived products (microbial 
metabolites) and metabolic products (SCFA, gut hormones) transport into host system 
through bloodstream and vagus system to induced CNS development and maintain 
brain homeostasis. In the disease model, when gut homeostasis is disrupted, the 
pathogenic bacteria outnumber beneficial bacteria. The gut integrity is damaged, and 
bacterial translocation occurs. The translocated bacteria and pathogen associated 
molecular patterns (PAMPs) activate peripheral immune cells to produce 
proinflammatory cytokines and chemokines. The cytokines and chemokines cross the 
blood brain barrier and exert deleterious effects directly on CNS. Simultaneously, the 
imbalance between beneficial bacteria and pathogenic bacteria results in abnormal 
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secretion of microbial metabolites, neurotransmitters and gut hormones, which have 
detrimental effects on BBB integrity, neurons, astrocytes and microglia, therefore, 
driving neurological disorders.  
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Figure 1.3 Mechanisms of morphine analgesic tolerance. 1. In opioid long-term 
treatment, the phosphorylated receptors are desensitized and retained on the membrane. 
2. β-arrestin binding to the receptor leads to internalization, degradation, and down-
regulation receptor on membrane. 3. Chronic morphine treatment super-activates 
adenylate cyclase (AC) activity and activates PKA/MAPK signaling pathways. 4. The 
activity of voltage-gated calcium channels are up-regulated to increase intracellular 
Ca2+, thus activating calmodulin kinase and PKC. These activated signaling pathways 
can modulate multiple targets including neurotransmitters, cytokines and chemokines, 
and their receptors, and related other proteins, thus contributing to analgesic tolerance. 
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5. Chronic morphine treatment activates N-methyl-d-aspartate (NMDA) receptors and 
suppresses glutamate transport on astrocytes to increase synaptic glutamate levels. 6. 
Non-neuronal cells such as microglia and astrocytes release inflammatory mediators 
through activation of toll-like receptors (TLRs). The released proinflammatory 
substances (inflammasomes, ATP, and calcitonin gene related peptide (CGRP), 
substance P, brain-derived neurotropic factor (BDNF)) sensitize the pre- and 
postsynaptic central neurons, contributing to tolerance. 7. Morphine directly binds to 
TLR4 to activate microglia and astrocytes. 8. TNF-α binds to endothelia of BBB to up-
regulate p-glycoprotein (P-gp) expression, thus exporting morphine molecules out of 
CNS to generate tolerance. 9. Chronic morphine induces gut dysbiosis, causes bacterial 
translocation and initiates local inflammation. The microbial components and pathogen 
associated molecular patterns (PAMP) circulate into CNS, activate non-neuron immune 
cells, result in increased expression of pro-inflammatory cytokines, and contribute to 
morphine tolerance. 10. Chronic morphine treatment depletes the beneficial bacteria 
with β-glucuronidase activity. The morphine metabolite morphine-3-glucuronide 
accumulates in the gut. Therefore, morphine could not recirculate back through 
enterohepatic recirculation. More morphine is needed to maintain the same analgesic 
effect.  
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CHAPTER 2 
GUT MICROBIOME CONTRIBUTES TO MORPHINE 
TOLERANCE 
INTRODUCTION 
Opioids are the gold standard for the management of moderate to severe pain(110). In 
spite of their high efficacy, the clinical use of opioids is limited because of co-
morbidities associated with their prolonged use(111). The last decade has seen a 
significant rise in opioid use in the United States resulting in a subset of the population 
developing opioid tolerance(112)(113). Chronic and repeated opioid use leads to the 
rapid onset of analgesic tolerance; however, the pharmacokinetics of tolerance to 
peripheral receptors develop slowly leading to respiratory depression, immune 
modulation, nausea and decreased gastrointestinal motility with escalating doses of 
opioids(114). Thus, chronic opioid use is associated with poorer outcomes, longer 
lengths of hospital stay, higher readmission rates and higher health care costs(54)(56). 
Therefore, it is imperative that we understand the mechanisms underlying the co-
morbidities associated with chronic opioid use and delineate specific protocols for the 
care of chronic pain patients that are on opioids. However, the precise mechanisms 
underlying morphine tolerance remain unresolved. Recent studies have shown that the 
gut microbiota plays a crucial and dynamic role in immune response and neuronal 
function(115). Gut homeostasis confers health benefits, and any disruption resulting in 
alteration in beneficial bacteria can negatively influence the health and wellbeing of an 
individual(1)(116). Toll-like receptors (TLRs) recognize a variety of microbial 
components and allow the innate immune system to sense and react to the altered 
microbiota, hence playing a central role in the interaction between host and 
microbiota(117).  
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Our recent studies have shown that chronic opioid use in animal models is associated 
with altered gut microbiota, with an expansion of Firmicutes and a decrease of 
Bacteroidetes (60)(118). These findings are supported by studies in patients with 
substance use disorder who demonstrate altered composition and diversity of gut 
microbiome distinct from healthy controls, thus implicating the gut-brain axis in 
morphine analgesic tolerance (64)(71)(119). In the present studies, we used multiple 
murine models to demonstrate the essential role of the gut microbiota in morphine 
analgesic tolerance. These studies suggest that strategies can be developed to alter the 
gut microbiota to prolong the effectiveness of morphine and prevent analgesic tolerance.   
 
MATERIALS AND METHODS 
Experimental animals  
Pathogen-free C57BL/6J mice were obtained from the Charles River Laboratories. All 
animals were housed in a specific-pathogen-free facility. All procedures were approved 
by Institutional Animal Care and Use Committee (IACUC) at the University of Miami. 
All mice (C57BL/6, TLR2KO, TLR4KO, and IL-6KO) were housed 3-5 per cage in 
SPF conditions and maintained on a 12-hour light/dark cycle in a constant temperature 
(20–22°C) and humidity (45–55%) with ad libitum access to food and water. GF mice 
were maintained in CBC flexible film isolators with sterile food and water. 
 
Animal treatment:  
Morphine sulfate (National Institutes of Health [NIH]/National Institute on Drug Abuse 
[NIDA], Bethesda, MD) was dissolved in sterile saline. Mice received constant dose of 
15mg/kg or escalating doses of (5, 10, 15, 20, 25, 30, 35, 40mg/kg) morphine injection 
b.i.d. On the ninth day, 25mg/kg morphine sulfate was used to test the anti-nociceptive 
 29 
response. According to established protocol, the non-absorbable pan-antibiotics 
cocktail (ABX) was prepared every day freshly in drinking water(120). The ABX 
treatment was given 7-10 days before morphine treatment and continued throughout 
the following eight days of morphine treatment and behavioral measurement.  
 
The mice were administrated with 5 g/L of streptomycin sulphate in the drinking water 
for 2 days and switched to normal drinking water for 24 hours before E. faecalis (EF) 
inoculation by oral gavage. The spectinomycin sulphate selective E. faecalis were 
diluted up to the concentration of 2 x 1010/mL in phosphate buffered saline (PBS). Each 
mouse was administered with 200μL spectinomycin solution by oral gavage daily. 
After 48 hours post gavage, the mice were treated with 250 mg/L spectinomycin sulfate 
(to prevent overgrowth of pathogenic gram-negative bacteria) in the drinking water 
during the behavior study. To maintain the population of E. faecalis in the mouse gut, 
mice were administered the same dose of E. faecalis and the same dose of 
spectinomycin sulphate by oral gavage daily during the behavior experiment for 8 days. 
 
Mice were orally gavaged with freshly prepared 5x1010 CFU of the probiotics VSL#3 
in 200µL water daily for 21 days before morphine treatment and maintained throughout 
the following eight days(121). 
 
Fecal Matter Transplantation (FMT):  
Twenty donor mice (10 mice for each batch) were injected with either morphine or 
saline b.i.d. as previously described. Their fecal contents were collected and pooled 
after sacrifice. The fecal content was processed according to the established protocol 
with modification(118). Briefly, 200mg of the fecal extract was suspended in 1mL 
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sterile PBS, filtered through 70µM cell strainer, and centrifuged at 6000Xg for 20min. 
About 1010 CFU/mL fecal bacteria were suspended in 6% NaHCO3 buffer with 20% 
sucrose. Each recipient mouse was treated with ABX as previously described and then 
orally gavaged with 200µL of freshly prepared fecal suspension on seven consecutive 
days before any downstream experiment or analysis. 
 
Behavioral study:  
The thermal nociceptive thresholds were assessed by both tail flick and hot plate assays 
as reference(122). The hot plate and tail flick analgesic responses were calculated as 
the percentage the maximum possible effect (%MPE). %MPE = (post-drug latency – 
pre-drug latency)/ (cut-off – pre-drug latency) × 100% for tail flick analgesia and hot 
plate. 
 
16S rRNA gene sequencing:  
Contents of ileum were collected under aseptic conditions from all mice after 
sacrificing. Sequencing and bioinformatics were performed by the University of 
Minnesota Genomic Center, MN, United States, and Microbiome Insights, Vancouver, 
BC, Canada. DNA was isolated using DNeasy PowerSoil® kits (Qiagen, Germantown, 
Maryland) modified to include a bead-beating step. At University of Minnesota, after 
DNA isolation, 16S ribosomal DNA hypervariable regions V5 and V6 were polymerase 
chain reaction amplified using primers with the V5F RGGATTAGATACCC and V6R 
CGACRRCCATGCANCACCT gene-specific sequences, Illumina adaptors, and 
molecular barcodes as described to produce 427 base pair (bp) amplicons. Samples 
were sequenced on an Illumina MiSeq (Illumina, San Diego, California) using MiSeq 
600 cycle v3 kit(123). In Microbiome Insights, the V4 region was amplified with 
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adapter-barcode-pad/linker-16S primer as shown below: 
AATGATACGGCGACCACCGAGTCTACACCTACTATATATGGTAATTGTGT
GCCAGCMGCCGCGGTAA and 
CAAGCAGAAGACGGCATACGAGATAACTCTCGAGTCAGTCAGCCGGACT
ACHVGGGTWTCTAAT. Samples were sequenced by Illumina MiSeq. 
 
Metagenomic data analysis:  
Primer sequences were removed from raw sequence reads and low-quality bases (Phred 
score<20) were trimmed from 3’ end using cutadapt(124). Microbial taxonomy 
assignment abundance quantification was analyzed with Greengenes database 
(ver.08/13) using dada2 pipeline. Microbial diversity between samples (b-diversity) 
was quantified by Bray-Curtis dissimilarity using R package “vegan”(125). The 
dissimilarity between pairs of treatment groups was assessed using permutation 
multivariate analysis of ANOVA (PERMANOVA) adjusting for the batch difference, 
and the significance of pair-wise comparison was adjusted for multiple comparison 
using Bonferroni correction. Individual differential taxa were identified accounting for 
batch difference using DESeq2 with significance determined based on a false discovery 
rate of 0.05 (FDR)(126). The raw sequencing data that support the findings of this study 
have been submitted to Sequence Read Archive (SRA) of the National Center for 
Biotechnology Information under accession number PRJNA531200.  
 
RESULTS 
1. Morphine treatment induced distinct gut microbiota community. 
To determine if microbial dysbiosis contributed to morphine analgesic tolerance, mice 
were treated with repeated morphine injections to induce analgesic tolerance. On day 
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8, small intestinal fecal contents were collected from WT morphine-tolerant mice and 
their corresponding saline-treated controls. Fecal DNA was extracted and subjected to 
16S ribosomal RNA sequencing. β-diversity analysis revealed a distinct clustering of 
the bacterial communities in the morphine-tolerant animals compared to saline-treated 
mice (p=0.00256, Permutation ANOVA test with Bonferroni correction) (Fig. 2.1).  
 
2. The Bifidobacteriaceae and Lactobacillaceae were reduced in morphine 
tolerant rodents. 
Further analysis revealed a reduction in the relative abundance of Actinobacteria at the 
phylum level in morphine-tolerant animals (Fig. 2.2A and Fig. 2.2B); Furthermore, 
morphine-tolerant animals displayed an expansion of Erysipelotrichaceae (Fig. 2.2C), 
Peptostreptococcaceae (Fig. 2.2D), Dehalobacteriaceae (Fig. 2.2E) and 
Ruminococcaceae (Fig. 2.2F), and a reduction in Caulobacteraceae (Fig. 2.2G), 
Comamonadaceae (Fig. 2.2H), Coriobacteriaceae (Fig. 2.2I) and Moraxellaceae (Fig. 
2.2J) at family level. At genus level, morphine-tolerant animals exhibited increased 
Allobaculum (Fig. 2.2M) and Oscillospira (Fig. 2.2N) and decreased [Ruminococcus] 
(Fig. 2.2O), Adlercreutzia (Fig. 2.2P), Acinetobacter (Fig. 2.2Q), Brevundimonas (Fig. 
2.2R), Turicibacter (Fig. 2.2S), and Delftia (Fig. 2.2T).  Notably, Bifidobacteriaceae 
(Fig. 2.2K) and Lactobacillaceae (Fig. 2.2L) at the family level and Bifidobacterium 
(Fig. 2.2U) and Lactobacillus (Fig. 2.2V) at the genus level were diminished in 
morphine-tolerant rodents.  
 
3. Morphine tolerance was attenuated in germ-free mice. 
To initially establish the role of the gut microbiota in morphine tolerance, GF mice and 
conventionally raised, specific-pathogen-free mice (SPF) were subjected to a well-
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established tolerance regimen wherein mice were treated with either saline or repeated 
escalating doses of morphine for 8 days. Interestingly, morphine-treated GF mice 
displayed less analgesic tolerance in both tail flick and hot plate tests than SPF mice, 
75% and 25% maximum possible effect (%MPE), respectively (Fig. 2.3 A and B).  
 
4. Morphine tolerance was recapitulated after germ-free mice receive naïve 
microbiota 
After GF mice that have undergone FMT with samples obtained from SPF naïve mice. 
These mice showed significant analgesic tolerance similar to SPF animals treated with 
morphine (Fig. 2.4 A and B). These results clearly establish the role of gut microbiota 
in morphine analgesic tolerance. 
 
5. Morphine tolerance was attenuated in pan-antibiotics-treated mice. 
To further investigate if gut microbial dysbiosis contributed to morphine tolerance, SPF 
mice were administered a cocktail of antibiotics in their drinking water for a week to 
deplete the gut microbiota and then treated with escalating doses of morphine for 8 days. 
Pan-antibiotics (ABX) treatment was maintained during the whole duration of 
morphine treatment. Results from these studies show that ABX markedly reduced gut 
bacteria (Fig. 2.5 A). ABX and SPF mice were treated with repeated escalating doses 
of morphine. The morphine-treated ABX mice showed significantly attenuated 
analgesic tolerance with 64 %MPE at day 8 in both tail flick (Fig. 2.5 B) and hot plate 
assays (Fig. 2.5 C). 8 days. In an additional study, a fixed morphine dose was 
administered to ABX and SPF control mice twice daily for 8 days. The ABX mice 
maintained a significantly higher antinociceptive efficacy from day 4 by tail flick (Fig. 
2.5 D) and from day 5 by hot plate (Fig. 2.5 E) compared to non-antibiotic-treated mice.  
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6. Morphine tolerance was mediated by FMT from morphine-treated mice. 
To further establish the role of gut microbiota in analgesic tolerance, SPF mice treated 
with ABX were gavaged with microbiota harvested from either saline- or morphine-
treated mice. Mice reconstituted with morphine-tolerant mouse microbiota and then 
treated with morphine showed exacerbated analgesic tolerance following the same 
daily injection doses. In contrast, mice that were reconstituted with saline-treated 
mouse microbiota displayed less analgesic tolerance (Fig. 2.6 A and B). To validate 
effective reconstitution, stool samples were collected from recipient mice and subjected 
to 16S ribosomal RNA sequencing. The microbiome of the recipient animals was 
similar to their donor profile in principal coordinates analysis (PCoA) clustering (Fig. 
2.6 C). In summary, the data from these studies clearly support a role for gut microbiota 
in morphine-induced analgesic tolerance. 
 
7. Morphine tolerance was exacerbated by pathogenic bacterial infection. 
Previously our lab demonstrated a significant expansion of Enterococcus faecalis in 
morphine-treated mice(60). In clinical studies, prescription opioids are associated with 
higher Enterococcus infection in septic patients(55). Therefore, we gavaged 
Enterococcus faecalis into mice to delineate the function of pathogenic bacteria to 
morphine tolerance. The mice infected with Enterococcus faecalis displayed more 
severe analgesic tolerance to morphine (Fig. 2.7 A, B) compared with morphine treated 
mice.   
 
8. Dysbiosis induced by morphine-tolerance was attenuated by VSL#3 probiotics.  
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Our previous microbial analyses showed that the relative abundance in the Operational 
Taxonomic Unit (OTUs) representing Lactobacillaceae and Bifidobacteriaceae were 
significantly reduced in morphine-tolerant animals. To investigate whether 
supplementation with these beneficial bacteria attenuated morphine tolerance, the mice 
were gavaged with probiotics VSL#3 21 days before morphine treatment. Measured by 
β-diversity, probiotics pre-treatment decreased morphine-induced microbial alterations, 
indicating that VSL#3 probiotics restored partial gut microbial components. (Fig. 2.8 
A) (p=0.00096 for Water+Morphine and Water+Saline, p=0.00012 for 
Water+Morphine and VSL#3+Saline, p=0.0024 for VSL#3+Morphine and 
Water+Saline, p=0.02592 for VSL#3+Morphine and VSL#3+Saline). At phylum level, 
morphine-induced reduction of Actinobacteria were supplied by VSL#3 (Fig. 2.8 B). 
Notably, bacterial communities (Bifidobacteriaceae, and Lactobacillaceae at family 
level, and Bifidobacterium, [Ruminococcus], and Lactobacillus at genus level) that 
were significantly reduced in relative abundance in morphine-tolerant animals were 
substantially restored compared to saline control sample. Peptostreptococcaceae, 
Prevotellaceae, Erysipelotrichaceae and Dehalobacteriaceae at family level, 
Prevotella, Allobaculum, Dehalobacerium at genus level, which were found 
significantly increased in morphine-tolerant mice, were decreased by probiotics 
supplementation (Fig. 2.8 C and D).  
 
9. Morphine tolerance was alleviated after gut microbiota was restored by VSL#3 
probiotics. 
After the mice were treated with probiotics VSL#3 for 21 days, the mice were treated 
with either escalating dose or constant dose of morphine. A dramatic decrease in 
morphine antinociceptive tolerance with VSL#3 pre-treatment was found compared to 
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sham mice following escalated morphine treatment in both tail flick (%MPE 34.74 vs 
54.23) and hot plate (%MPE 30.04 vs 51.09) tests (Fig. 2.9 A and B). Similarly, 
probiotics pre-treatment alleviated morphine tolerance after 15mg/kg constant doses of 
morphine treatment (Fig. 2.9 C and D). 
 
10. The morphine-induced gut dysbiosis was prevented in TLR2KO and TLR4KO 
mice 
After the TLR2KO and TLR4KO mice received the same doses of saline or morphine 
as WT mice, small intestinal fecal contents were collected as WT morphine-tolerant 
mice and their saline-treated controls. We found no significant difference in the β-
diversity matrix comparing morphine and saline-treated animals (p=0.21668, Fig. 2.10 
A, p=0.1833, Fig. 2.10 B). The differential bacterial profile that we observed in WT 
mice was not observed either in TLR4KO and TLR2KO mice. Furthermore, TLR2KO 
mice shows less bacterial profile changes compared to TLR4KO mice after chronic 
morphine administration. These data imply that the microbiota of TLR2KO and 
TLR4KO are very stable and resist to any change as a consequence of morphine 
treatment (Fig. 2.10 C, D and E). 
 
11. Morphine tolerance was attenuated in TLR2KO and TLR4KO mice 
To further delineate the roles of TLR2 and TLR4 in morphine analgesic tolerance, 
TLR2 and TLR4 Knockout (TLR2KO and TLR4KO) mice were treated with repeated 
injections of morphine (either with escalated or fixed doses). We found that morphine-
induced analgesic tolerance was partially attenuated in both TLR2KO and TLR4KO 
mice using either tail flick (Fig. 2.11 A) or hot plate (Fig. 2.11 B) assays in escalating 
dose model and constant dose model (Fig. 2.11 C and D). Although morphine-induced 
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analgesic tolerance was modulated by both TLR2 and TLR4, it was more significantly 
attenuated in TLR2KO mice. This suggests a more important role for TLR2 in 
morphine analgesic tolerance. 
 
12. Morphine-induced gut dysbiosis was attenuated in IL6KO mice 
As previous literature indicated that proinflammatory cytokines play a key factor in 
morphine analgesic tolerance. Here we used IL-6KO mice to detect whether IL-6 have 
an effect on gut dysbiosis in the morphine-tolerant model. The IL-6KO mice did not 
exhibit a significantly distinct bacterial profile after chronic morphine treatment as WT 
mice (IL6KO_Morphine vs IL6KO_Saline, p= 0.84244, Fig. 2.12 A, B). Furthermore, 
the dramatic accumulation of Verrucomicrobiaceae, S24-7, and Clostridiaceae at 
family level, Akkermansia and Clostridium at genus level in morphine tolerant mice 
were not observed in IL-6KO mice. Notably, the decrease of Lactobacillaceae and 
Bifidobacteriaceae at family level and Lactobacillus and Bifidobacterium at genus 
level in WT tolerant mice were not observed in IL-6KO morphine treated mice (Fig. 
2.12 C, D). Taken together with previous TLR2KO and TLR4KO microbial profiles, it 
implies that immune system plays a key role in maintaining bacterial habitat in the gut. 
It is speculated that IL-6 proinflammatory cytokine induced by chronic morphine 
treatment makes a deleterious environment for beneficial bacteria such as 
Lactobacillaceae and Bifidobacteriaceae to survive and proliferate.  
 
13. Morphine-induced tolerance was alleviated in IL6KO mice 
Since morphine-tolerant animals showed a significant increase in IL-6 protein levels, 
we hypothesized that IL-6 may be one of the mediators of morphine tolerance. To test 
this hypothesis, IL-6 Knockout (IL-6KO) mice were subjected to repeated morphine 
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injections to induce analgesic tolerance. Analgesic tolerance for both tail flick (30.23 
vs 42.82 %MPE) and hot plate assays (23.44 vs 35.89 %MPE) (Fig. 2.13 A, B, C and 
D) were only partially attenuated in these mice indicating that other proinflammatory 
cytokines may also contribute to modulating analgesic tolerance.  
 
DISCUSSION 
In previous and current studies, we showed the adverse effects of morphine-induced 
dysbiosis. The modification of gut microbiome implicates the mediators and 
consequences of the communication between gut and brain. Our findings identify that 
gut microbiome plays a causative role through initiating inflammation by TLR2 and 
TLR4 activation, resulting in morphine-induced analgesic tolerance. We used ABX and 
GF mice to prove that elimination of gut microflora retained analgesic efficacy, and the 
morphine tolerance restored after recolonizing gut microbiota. After replenishing the 
missing gut bacteria, especially Bifidobacteriaceae and Lactobacillaceae by VSL#3 
probiotics, we found that morphine analgesic tolerance was attenuated. In addition, 
morphine analgesic tolerance was exacerbated in pathogenic Enterococcus faecalis 
infection model. Taken together, these findings implicated the fundamental role of 
microbiota in the opioid-induced analgesic tolerance. 
 
There are now a large and accumulating body of evidence demonstrating that gut 
bacteria have the capacity to regulate CNS homeostasis and have given rise to the 
concept of the microbiota-gut-brain axis which relays a variety of interaction between 
the CNS and the gastrointestinal tract. However, the precise details of the mechanisms 
are not fully understood. In morphine tolerant mice, at family level, 
Peptostreptococcaceae, Erysipelotrichaceae, and Dehalobacteriaceae were found 
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more abundant in morphine tolerant mice. Bajaj group showed that the opioid users had 
higher endotoxemia. Moreover, IL-6 level and Peptostreptococcaceae were found 
increased in these chronic opioid users(48). Other studies implied that 
Peptostreptococcaecae also found to be significantly more abundant in post-stroke, 
rotenone-induced Parkinson Disease(12), and non-alcoholic fatty liver disease(127). 
Moreover, an increase of Peptostreptococcaeca is associated with metabolic disease 
after 30 days of high fat diet(128). Inflammation and low fiber diet related family 
Erysipelotrichaceae was more abundant in APP/PS1 mice of Alzheimer’s diseases and 
PD-1 knockout mice with high chance of sepsis compare to C57BL/6 mice(129). Its 
abundance level were found to enrich in the lumen of colorectal cancer patients as 
compared to healthy controls(130). Previously in our lab, the abundance of 
Enterococcus  and Erysipelotrichaceae were negatively correlated with cholic acid and 
octadecanedioic acid while positively associated with phosphatidylethanolamines and 
stearic acid in morphine-treated mice(60). It indicated that immune and metabolic 
pathways were both considered to play a part for exacerbating morphine analgesic 
tolerance. 
  
In the chronic morphine-treated group, Comamonadaceae, Coriobacteriaceae, 
Moraxellaceae, and Caulobacteraceae were found significantly decreased. 
Coriobacteriaceae were found significantly decreased in patients with a higher 
pouchitis disease activity index(131). The pouchitis was also inversely correlated with 
Moraxellaceae indicated by erythrocyte sedimentation rate and fecal lactoferrin(132). 
The abundance of Moraxellaceae and Lachnospiraceae were found decreased in 
chronic alcohol-treated mice(133).  
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At genus level, the abundance of Allobaculum from the family of Erysipelotrichaceae 
were up-regulated. It has been reported that high cholesterol diet (HCD) induced 
changes in gut microbiota and inflammation. The Allobaculum, which was found 
increased after HCD, exhibited a negative correlation with colonic expression of anti-
inflammatory genes such as Foxp3, IL-10, occludin and ZO-1(134). The 
Dehalobacterium were also found increased after high fat diet. It is correlated with 
intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver 
disease(135). The abundance of Oscillospira were found higher in old SPF mice. This 
age-related gut dysbiosis associated with intestinal permeability, systemic 
inflammation and macrophage dysfunction(136). However, [Ruminococcus], 
Adlercreutzia, Acinetobacter, Brevudimonas, Delftia, and Turicibacter were found 
decreased after morphine treatment. In the Multiple Sclerosis patients, Adlercreutzia 
with Prevotella were found decreased, indicating their contribution to the inflammatory 
processes in neurological disorders(137). However, Gram-negative bacteria 
Acinetobacter were found translocated into mesenteric lymph nodes, spleen and livers, 
involving in the neuroinflammation in rat depression model(138). Turicibacter, which 
abundance is decreased in die-induced obesity, associated with increased intestinal 
inflammation and alterations of the Wnt pathway towards tumorigenesis(139). Taken 
together, although the specific roles of these bacteria in morphine tolerance model have 
not been delineated, the growing literature implies that dysbiosis might have an 
influence on analgesic tolerance through modulating gut homeostasis including 
metabolism, immune activation and gut barrier disruption.  
 
The dramatic depletion of Bifidobacterium and Lactobacillus, two essential and 
common inhabitants of the human intestine, were of particular interest because of their 
 41 
roles in maintaining gut homeostasis and gut epithelial integrity(140). Bifidobacterium 
and Lactobacillus with anti-inflammatory and antioxidative properties are also shown 
to be significantly decreased in aging and in Alzheimer’s patients with concomitant 
increase in intestinal permeability and inflammation(141). Together our studies imply 
the reduction in these two bacterial communities plays a crucial role in morphine 
tolerance. The enrichment of Bifidobacteria and Lactobacteriaceae by VSL#3 
administration are resistant against pathogens and preserve the gut homeostasis. VSL#3 
supplementation suppressed the abundance of these pathogens including 
Peptostreptococcaceae, Erysipelotrichaceae, Prevotellaceae, Dehalobacteriaceae, 
Allobaculum, Prevotella, Dehalobacterium.  However, it could not inhibit the 
decreased of Moracellaceae and Acinetobacter. After administration of VSL#3 
probiotics, Lactobacillaceae and Bifidobacterium were restored in the mice ileum. 
There are studies implying Lactobacillaceae were negatively associated with 
neuroinflammation in cirrhosis in mice(142). Bifidobacterium longum NCC3001 
attenuated anxiety-like behavior in mice with infectious colitis(44). In conclusion, 
microbiota as the “forgotten organ” is a key factor in maintaining gut and neuronal 
homeostasis. The imbalance of bacteria in the gut due to chronic morphine treatment 
contributes to analgesic tolerance. 
 
In the pan-antibiotics treated mice, we observed less analgesic tolerance after chronic 
morphine treatment. Though a broad-spectrum antibiotic approach reduced the 
majority of bacterial species, there will still bacterial left in the gut that was not 
detectable by gel electrophoresis. Furthermore, although Pimaricin in pan-antibiotics 
combination was anti-fungi, the other bacteriophages and eukaryotic virus, which were 
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not directly targeted by bactericidal antibiotics, cannot be ignored. Thus, we used both 
broad-antibiotics treatment model and germ-free mice model.  
 
Depletion of the gut microbiome with broad spectrum antibiotics and/or absence of the 
gut microbiome as in GF mice have revealed the critical role of the gut microbiome in 
the behavior, stress- and pain-modulation systems, and central neurotransmitter 
systems(20)(143)(144). The GF mice exhibited reduced anxiety-like behavior, 
impaired short-term recognition and working memory, increased stereotyped and 
repetitive behavior(145). GF mice also alleviated neurological diseases such as EAE 
and Alzheimer’s disease(146)(147). The gut microbiome, as a potential contributor to 
morphine analgesic tolerance, was previously implicated in studies by Kang et al. 
wherein they demonstrated that pan-antibiotics attenuated morphine tolerance tested by 
tail immersion, acetic acid stretch and tail flick assays. Notably, the vancomycin along, 
which targets gram-positive bacteria, is sufficient to inhibit morphine tolerance 
generation. However, the combination of streptomycin, neomycin, vancomycin and 
metronidazole have the best effects(69). It indicates that gram-positive bacteria are 
pivotal for morphine-induced analgesic tolerance. Moreover, although pan-antibiotics 
could not change morphine concentration in the brain, it reversed morphine-induced 
reduction in electrical excitability of DRG neurons (69). In their following studies, they 
demonstrated that gut-derived mediators produced by morphine-induced dysbiosis 
were responsible for the development of morphine tolerance by regulating the DRG 
neuron through tetrodotoxin-resistant (TTX-R) Na+ and TRPV1 channels(148). Both 
our studies and their research demonstrated that morphine-induced dysbiosis provides 
a detrimental peripheral environment to exert its influence on CNS by producing 
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bacterial products, inducing proinflammatory cytokines, activating TLR2/4 and 
sensitizing of TTX-R Na+ channel.  
 
In another study, the mice spend significantly more time in the cocaine-paired chamber 
after repeated cocaine injection, indicating cocaine abuse and dependence. However, 
antibiotics-treated mice did not show preference to cocaine-related chamber in 
conditioned place preference experiment. Moreover, mice receiving gut microbiota 
from morphine-treated mice exhibited no preference to cocaine. These studies imply 
that morphine-induced dysbiosis regulates rewarding and addiction, in addition to 
morphine tolerance(70).  
 
Taken together, these studies provide strong support for the role of the gut microbiome 
in the development of morphine analgesic tolerance, addition and rewarding, and 
support targeting the microbiome as a druggable site for prolonging the analgesic 
efficacy of morphine for pain management. 
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Figure 2.1 Multidimensional scaling analysis of gut microbiota to visualize the Bray-
Curtis distance of WT morphine tolerant mice and their controls. Red circles depict 
samples from morphine-tolerant mice; blue triangles represent WT saline-treated mice. 
β-diversity was found to be significantly different between the WT morphine-tolerant 
and saline-treated groups (p=0.00256). 
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Figure 2.2 Microbiota alteration after 8 days of chronic morphine treatment. (A) 
Taxonomic distribution of WT morphine-tolerant mice and their controls at phylum 
level. Each column represents the fecal sample from one mouse. (B-V) Relative 
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abundance of each bacteria community in saline and chronic morphine treatment 
groups.  
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Figure 2.3 Morphine tolerance was attenuated in GF mice compared to SPF mice under 
the same dose of morphine treatment. (A, B) Antinociceptive tolerance was alleviated 
in GF mice. Ftail flick (3,10) = 869.4 and Fhot plate (3,10) = 110.9. Data were analyzed by 
one-way ANOVA followed by Bonferroni correction. **, p<0.01; ****, p < 0.0001. 
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Figure 2.4 GF mice recapitulated morphine tolerance after FMT with naïve mouse 
microbiota. (A, B) The GF mice were gavaged with microbiota from naïve SPF mice 
for 7 days. Then the mice were administered escalating doses of morphine. Ftail flick (3,10) 
= 882.8 and Fhot plate (3,10) = 147.8. nSPF=4, nGF=3. Data were analyzed by one-way 
ANOVA followed by Bonferroni correction. ****, p < 0.0001. 
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Figure 2.5 Analgesic tolerance was alleviated in ABX-treated mice. (A) Representative 
image of PCR product of bacterial 16S rRNA gene on electrophoresis gel. A: ABX + 
Saline-treated mice; AM: ABX + Morphine-treated mice; n=7 for each group. Bac., 
bacterial DNA; Untreated, ABX untreated mice as positive controls. (B, C) Mice 
exhibited attenuated analgesic tolerance after gut microbiota depletion. n=12-20. (D, E) 
Time course of ABX treatment on morphine tolerance. n=10-16, presented as Mean ± 
SD. FTreatment x time (35, 434) = 52.46 for tail flick. FTreatment x time (35, 434) = 60 for hot 
plate. Significance was assessed by two-way ANOVA followed by Tukey’s multiple 
comparisons method. **, p<0.01, ****, p<0.0001. 
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Figure 2.6 Morphine analgesic tolerance was regulated by gut microbiota manipulation. 
(A) Multidimensional scaling analysis plot of stool samples based on Bray-Curtis 
distance. The microbiome of recipient mice was similar to the donor mice after FMT 
(Saline_Recepient vs Saline_Donor, p=0.282; Morphine_Recepient vs 
Morphine_Donor, p=0.33612, Permutation ANOVA test). NMDS: non-metric 
multidimensional scaling. Time course of the effects of different microbiota on 
morphine tolerance. n=6-8. FTreatment x time (56, 343) = 73.15 for tail flick. FTreatment x time 
(56, 343) = 59.66 for hot plate. Two-way ANOVA followed by Tukey’s multiple 
comparison was used. *, p<0.05; **, p<0.01; ***, p< 0.001; ****, p<0.0001 Morphine vs 
Saline microbiome + Morphine; *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001 
Morphine vs Morphine microbiome + Morphine. Each dot represents one mouse. Mean 
± SD. MPE: maximum possible effect. 
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Figure 2.7 Enterococcus faecalis infection accelerated the generation of morphine 
analgesic tolerance. (A, B) Morphine analgesic effect was determined everyday by both 
tail flick and hot plate. n=6-10. Statistical analyses were carried out by two-way 
ANOVA followed by Tukey’s multiple comparison method. Ftail flick (35, 252) = 86.77. 
Fhot plate (35, 252) = 127.0. 
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Figure 2.8 VSL#3 partially restored morphine-induced gut dysbiosis. (A) 
Multidimensional scaling was used to visualize the Bray-Curtis distance of different 
groups. n=9-15. Data were subjected to permutation ANOVA test along with 
Bonferroni correction. (B) Taxonomic distribution of different groups at phylum level. 
(C, D) Dot plots show changes in abundance of bacteria in Water+Morphine- and 
VSL#3+Morphine- treated mice at family and genus level using Water+Saline mean 
proportion as reference. n=9-15. 
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Figure 2.9 Probiotics VSL#3 pre-treatment attenuated morphine tolerance and 
prevented morphine-induced gut microbiota alteration. (A, B) Morphine analgesic 
effect was determined after escalating doses of morphine. n=10-20. Ftail flick (3, 51) = 
46.78. Fhot plate (3, 51) = 82.50. One-way ANOVA followed by Bonferroni’s correction 
was used to analyze data. (C, D) Time course of morphine tolerance was assessed by 
tail flick and hot plate tests. Mice were gavaged with probiotics and treated with 
constant doses of morphine. Data represent mean ± SD from 10-20 mice. Statistical 
analyses were carried out by two-way ANOVA followed by Tukey’s multiple 
comparison method. FTreatment x time (35, 490) = 143.0 for tail flick. FTreatment x time (35, 490) 
= 126.2 for hot plate. 
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Figure 2.10 Morphine analgesic tolerance resulted in gut dysbiosis in WT mice, not in 
TLR2KO and TLR4KO mice. (A, B) Multidimensional scaling analysis of gut 
microbiota to visualize the Bray-Curtis distance of TLR2KO and TLR4KO morphine 
tolerant mice and their controls. Red circles depict samples from morphine-tolerant 
mice; blue triangles represent saline-treated mice. β-diversity was found to be 
significantly different between the WT morphine-tolerant and saline-treated groups 
(p<0.001). (C) Taxonomic distribution of TLR2KO and TLR4KO morphine-tolerant 
mice and their controls at phylum level. Each column represents a fecal sample from a 
treatment group. (D, E) dot plots show changes in abundance of bacteria with morphine 
treatment in WT, TLR2KO and TLR4KO at family and genus level using WT saline 
mean proportion as reference. Microbial taxa with significant difference in WT mice 
were selected at False Discovery Rate (FDR)<0.1 and average relative abundance of 
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WT control > 0.1%; nTLR2KO=19-24; nTLR4KO=8-11. NMDS: non-metric 
multidimensional scaling. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 56 
 
Figure 2.11 Both TLR2KO and TLR4KO exhibited alleviated analgesic tolerance. (A, 
B) Morphine analgesic tolerance was determined in WT, TLR2KO and TLR4KO mice. 
Ftail flick (5, 46) = 75.71. Fhot plate (5, 46) = 42.04. n=8-10. (C, D) WT, TLR2KO and 
TLR4KO mice were treated with constant doses of morphine twice daily. FTreatment x time 
(56, 329) = 23.09 for tail flick.  FTreatment x time (56, 329) = 103.5 for hot plate. Data were 
analyzed by two-way ANOVA followed by Tukey’s multiple comparison method. 
*WT Morphine compared to TLR2KO Morphine, *WT Morphine compared to 
TLR4KO Morphine, *TLR2KO Morphine compared to TLR4KO Morphine. 
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Figure 2.12 Chronic morphine-induced gut dysbiosis was abrogated in IL-6KO mice. 
(A) Multidimensional scaling analysis of gut microbiota to visualize the weighted 
Unifrac distance of saline- and morphine- treated IL-6KO mice. (B) Taxonomic 
distribution of IL-6KO and WT morphine-tolerant mice and their controls at phylum 
level. Each column represents one mouse sample from a treatment group. (C, D) dot 
plots show changes in abundance of bacteria with morphine treatment in WT and IL-
6KO mice at family and genus level using WT saline mean proportion as reference. 
Microbial taxa with significant difference in WT mice were selected at False Discovery 
Rate (FDR)<0.1 and average relative abundance of WT control > 0.1%; nIL-6KO=6-9; 
nWT=12. NMDS: non-metric multidimensional scaling. 
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Figure 2.13 (A, B) WT and IL-6KO mice were treated with escalating morphine dosing 
for 8 days. n=13-17. Ftail flick (3, 56) = 206.1. Fhot plate (3, 56) = 268.9. Data were analyzed 
by one-way ANOVA followed by Bonferroni’s multiple comparisons test. (C, D) WT 
and IL-6KO mice were treated with constant doses of morphine for 8 days. n=4-10. 
Data were analyzed by two-way ANOVA followed by Tukey’s multiple comparison 
method. FTreatment x time (35, 321) = 83.33 for tail flick. FTreatment x time (35, 321) = 79.3 for 
hot plate. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001. Mean ± SD. 
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CHAPTER 3 
THE MECHANISMS OF MORPHINE-INDUCED DYSBIOSIS 
CONTRIBUTING TO ANALGESIC TOLERANCE 
INTRODUCTION 
Morphine, as a narcotic pain reliever, is used to treat moderate to severe pain. However, 
morphine-induced analgesic tolerance often limits it usefulness in the long-term 
treatment of pain. The mechanisms underlying tolerance are not well understood. 
Studies on opioid analgesic tolerance have revealed several potential mechanisms: 
receptor desensitization and downregulation(101), upregulation of cAMP-protein 
kinase A (PKA) systems, release of glutamate, calcitonin-gene-related-peptide (CGRP), 
substance P (SP), noradrenaline, and acetylcholine to enhance synaptic 
transmission(149) and neuroimmune activation and neuroinflammation 
(75)(93)(150)(151)(152) (153) (154). 
 
Recent studies show a strong association between inflammation and analgesic 
tolerance(75). It is postulated that chronic morphine treatment activates microglia cells 
and astrocytes to produce pro-inflammatory cytokines and chemokines IL-1β, TNF-α, 
IL-6, and CX3CL1(155). By acting in an autocrine/paracrine manner, the 
proinflammatory factors and their receptors are upregulated on immune cells, 
amplifying the mediators release and exacerbating morphine tolerance. Molecules and 
drugs are designed to determine the function of these inflammatory mediators and 
related signaling pathways in morphine tolerance. Resveratrol, Ibudilast and 
Minocycline are anti-inflammatory drugs have been shown to alleviate morphine 
tolerance(156)(157)(158). Thalidomide attenuates development 
of morphine dependence in mice by inhibiting PI3K/Akt and nitric oxide signaling 
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pathways(159). Glibenclamide suppresses NLPR3, thus inhibiting the activation of 
caspase1 to generate mature IL-1β(92). However, the precise mechanisms how 
inflammation regulates morphine tolerance have not been completely elucidated yet.  
 
We have previously shown that morphine treatment compromises intestinal barrier 
function and induces bacterial translocation(59). Further studies demonstrated that 
morphine treatment induces a distinct shift of gut microbiota. Thus, we hypothesize 
that morphine-induced dysbiosis lead to gastrointestinal pathological changes and thus 
can have an impact on morphine analgesic tolerance. In this study, we aim to establish 
a link between gut dysbiosis and gut barrier compromise, bacterial translocation, and 
morphine analgesic tolerance.  
 
Intestinal dysbiosis is a complication observed in a myriad of extra-intestinal disorders 
and diseases including neuropsychiatric disorders, tumor, metabolic disease, allergic 
disorder, and autoimmune diseases(116). Antibiotics are found to have neuroprotective 
properties against neurodegenerative and neuroinflammatory processes in Parkinson’s 
Disease(18), Experimental Autoimmune Encephalomyelitis (EAE)(160), Multiple 
Sclerosis, and Transmissible Spongiform Encephalopathies(161). Furthermore, 
alcohol-induced neuroinflammation and small intestinal inflammation were abrogated 
following antibiotics administration(162). These studies highlight the fundamental role 
of gut microbiota in disease condition. However, it is still unknown whether morphine-
induced dysbiosis contribute to morphine-induced neuroinflammation and thus 
analgesic tolerance. The current study therefore focuses on the role of morphine-
induced dysbiosis on neuroinflammation as a mechanism contributing to analgesic 
tolerance.  
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Previously, Meng et al. demonstrated that morphine-induced bacterial translocation 
was alleviated in TLR2KO and TLR4KO mice. TLR2 and TLR4 modulate the tight 
junction organization in a MLCK-dependent manner. Therefore, less gut epithelial 
disruption was found in TLR2KO and TLR4KO mice(59). In addition, TLR2 and TLR4 
are receptors for gram-positive and gram-negative bacteria, respectively. The pathogen 
associated molecular pattern (PAMP) such as LTA and LPS binds to TLR2 and TLR4 
separately and initiates a cascade of events leading to significant immune response. 
Simultaneously, our lab found that morphine treatment enhances the TLR2 and TLR4 
expression on microglia(163). Studies have indicated that damaged associated 
molecular patterns (DAMP) such as Heat Shock Protein (HSP)70, HSP90, High-
mobility group box 1 (HMGB1) are generated during chronic morphine treatment. 
These PAMPs and DAMPs activate TLR2 and TLR4 on the microglia and astrocytes 
to produce cytokines such as TNF-α, and various interleukins such as IL-6, IL-1β, IL-
8, IL-12 (92). Therefore, we hypothesize that gut dysbiosis and following bacterial 
translocation and inflammation contribute to analgesic tolerance through activation of 
TLR2 and TLR4.  
 
To further prove the cross-correlation association between morphine-induced dysbiosis 
and morphine-associated abnormalities, we plan to use Fecal Microbiota 
Transplantation (FMT). For instance, cirrhotic patients suffer from persistent cognitive 
impairment. In the mouse model of cirrhosis, the mice undergoing FMT with 
microbiota from cirrhosis patients displayed greater neuroinflammation, microglial 
activation and GABAergic activation and lower synaptic plasticity compared to mice 
undergoing FMT with healthy controls(164). Furthermore, FMT, as a therapeutic 
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method, alleviates the symptom of neuropsychiatric disease and neurodegenerative 
disease. The FMT studies have been applied to ulcerative colitis, inflammatory bowel 
disease, Parkinson’s disease, multiple sclerosis, myoclonus dystonia, chronic fatigue 
syndrome, and idiopathic thrombocytopenic purpura, which have shown favorable 
outcomes(165). Therefore, FMT of microbiota from chronic morphine-treated mice 
will allow us to gain insight into the mechanisms how gut microbiota contributes to 
morphine-induced gut pathogenesis and behavior changes. It might be an alternative 
therapeutic method to alleviate morphine-induced neuronal malfunction. Previously 
Banejee et al. studies have shown mice with FMT from morphine-treated mouse 
exhibited “morphine-like” diseased phenotype with damaged epithelial morphology, 
bacterial translocation and escalating IL-6 expression in liver(118). However, it is still 
unclear if there is a direct cause-consequence relationship between dysbiosis and 
morphine-induced neuroinflammation. Therefore, in this study, we plan to use the FMT 
approach to detect how morphine-induced dysbiosis exert its influence on TLR2/4 
expression, bacterial translocation, gut integrity and peripheral and neuroinflammation.  
 
The beneficial effects of probiotics are not only limited to gastrointestinal tract. In the 
gut, the underlying mechanisms of advantageous effects of probiotics include 
immunomodulatory effects, inhibition of pathogen colonization, production of 
bacteriocin-like inhibitory compounds against pathobiome, production of metabolites, 
lowering of pH and reinforcement of gut epithelial integrity(166). Therefore, probiotics 
contribute to central nervous system and behavior changes through gut-brain axis. For 
instance, the combination between Bifidobacterium animalis and Lactobacillus 
plantarum ameliorate neuroinflammation in multiple sclerosis by favoring Th2 and 
Treg differentiation via up-regulation of Foxp3 and GATA3(167). It has been shown 
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by our lab and other research groups that Lactobacillus was diminished in morphine-
treated group(118)(70). Previously in chapter 2, we have demonstrated that morphine 
tolerance was alleviated after Lactobacillus was restored. However, it is not yet clear 
how Lactobacillus (VSL#3 probiotics) exerts its neuroprotective effect in chronic 
morphine model. Here we hypothesize that VSL#3 pretreatment suppresses morphine-
induced neuroinflammation by alleviating the symptoms of bacterial translocation, gut 
epithelial integrity and intestinal inflammation.   
 
In this study, we will use antibiotics-treated mouse model, germ-free (GF) mouse model, 
FMT model and probiotics treatment model to detect the role of morphine-induced 
dysbiosis in CNS abnormalities, therefore contributing to morphine tolerance. We 
hypothesized that morphine-induced dysbiosis has a detrimental effect on central 
nervous system by disrupting peripheral gut epithelial barrier function leading to 
bacterial translocation and local inflammation. We propose probiotics as a promising 
approach in the manipulation of the intestinal microbiota with tremendous potential 
applications in the morphine-induced behavior changes.   
 
MATERIALS AND METHODS 
Intestinal permeability and bacterial translocation: 
 To access in vivo intestinal permeability, 600 mg/kg of FITC-dextran (wt 4000; Sigma-
Aldrich) was orally gavaged into mice 4 hour prior to blood collection. After sacrifice, 
serum FITC-dextran fluorescence intensity was measured by SpectraMax® i3x. MLN 
and liver tissue were collected, homogenized and cultured on BD™ Trypticase™ Soy 
Agar plates with 5% Sheep Blood (TSA II™) to determine bacterial translocation.  
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Real-Time PCR:  
Total RNA from spinal cord and ileum was extracted using TRIzol (Invitrogen). cDNA 
was synthesized using the M-MLV Reverse Transcription kit (Promega) following 
manufacturer’s protocol. Primers for IL-6, IL-1β, TNF-α, and GAPDH were purchased 
from Invitrogen. Quantitative real-time polymerase chain reaction was performed using 
LightCycler® 480 SYBR Green I Master (Roche). GAPDH was used to normalize 
values. The results were analyzed by the relative quantity (ΔΔCt) method. Primer 
sequences: GAPDH: 5’-ACGGCAAATTCAACGGCACAGTCA-3’, 5’-
TGGGGGCATCGGCAGAAGG-3’; IL-6: 5’-
TGGCTAAGGACCAAGACCATCCAA-3’, 5’-
AACGCACTAGGTTTGCCGAGTAGA-3’; TNF-α:  5’-
CCTCCCTCTCATCAGTTCTATGG-3’, 5’-CGTGGGCTACAGGCTTGTC-3’; IL-
1β: 5’-GGCAGGCAGTATCACTCATT-3’, IL-1β: 5’-
AAGGTGCTCATGTCCTCATC-3’. 
 
PCR:  
Bacterial DNA was isolated from mouse tissues as previously described. The 16S 
ribosomal RNA (rRNA) gene was amplified by 5’-
TTGGAGAGTTTGATCCTGGCTC-3’, and 5’-ACGTCATCCCCACCTTCCTC-3’.  
Gram-positive and gram-negative bacterial DNA was amplified by NF with N6R, and 
NF with NR and P2F, respectively. NF: 5’-
GGCGGCAKGCCTAAYACATGCAAGT-3’, NR: 5’- 
GACGACAGCCATGCASCACCTGT-3’, P2F: 5’-GCGRCTCTCTGGTCTGTA-3’, 
N6R: 5’-GGTGCCTTCGGGAAC-3’. Amplified DNA was visualized using 1% 
agarose electrophoresis gel(168).   
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Intestinal cell isolation and FACS:  
Intestinal cell isolation was performed as previously described(169). Single cell 
suspensions were incubated with a mixture of antibodies: Pan-Keratin (C11) Mouse 
mAb (Alexa Fluor® 488 Conjugate, cell signaling), redFluor™ 710 Anti-Mouse CD45 
(30-F11, Tonbo bioscience), Ghost Dye™ Red 780 (Tonbo bioscience), and either 
BV421 Rat Anti-Mouse CD282 (TLR2, BD bioscience) or BV421 Rat Anti-Mouse 
CD284 (TLR4, BD bioscience). The data were collected and analyzed by cytoExpert 
software with cytoFlex S (Beckman Coulter). The figures were made by Kaluza.  
 
ELISA:  
The concentrations of IL-6, IL-1β and TNF-α in brain, liver and MLN were quantified 
using enzyme-linked immunosorbent assay kits (Fisher Scientific).   
 
Histology:  
Sections of formalin-fixed paraffin-embedded gut tissues were subjected to H&E 
staining for the evaluation of morphine-induced morphological disruption of gut 
epithelial integrity as previously described(59).  
 
Statistical analysis:  
Experimental data were analyzed using Prism 6 (GraphPad Software, Inc.). Parametric 
data were compared using Student’s t-test. For multiple-group comparison, data were 
analyzed by ANOVA one-way analysis, followed by Bonferroni correction or two-way 
analysis, followed by Tukey’s multiple comparison method.  
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RESULTS 
1. Gut microbiota was responsible for morphine-induced gut pathology. 
After SPF mice were injected with 15mg/kg morphine twice daily for 8 days, ileum 
samples were dissected and examined for histopathological changes. In SPF morphine-
tolerant mice, we observed impaired epithelia and increased inflammatory infiltrates in 
small intestinal villi (Fig. 3.1 A, B). In contrast, in morphine-treated GF and ABX mice, 
no morphological damage was observed (Fig. 3.1 C, D, E, F). Morphine-induced 
intestinal disruption was also seen in GF mice that received naïve microbiota from SPF 
mice (Fig. 3.1 G, H). In the GF or ABX mice undergoing FMT from saline- or 
morphine-tolerant mice, we observed that FMT from morphine-tolerant mice alone was 
sufficient to induce histopathological change in the gut without requiring direct 
exposure to morphine (Fig. 3.1 I, J, K, L).   
  
2. Gut microbiota contributed to gut leakiness in morphine-tolerant mice. 
To evaluate the disruption in gut permeability, SPF and ABX mice with or without 
FMT were gavaged with fluorescein isothiocynate (FITC)-dextran. Significant increase 
in gut permeability was observed in SPF morphine-tolerant mice (Fig. 3.2 A). 
Morphine’s effect on gut permeability of SPF mice was abolished in ABX-treated mice 
(Fig. 3.2 A). In ABX mice that underwent FMT, a significant increase in FITC-dextran 
in the serum was observed in the mice receiving gut microbiota from morphine-tolerant 
mice (Fig. 3.2 B), but not in those receiving gut microbiota from saline-treated mice. 
 
3. Gut microbiota attributed to bacterial translocation in morphine tolerant mice. 
We next evaluated gut bacterial translocation to the liver and mesenteric lymph nodes 
(MLN) in the mice. Significant bacterial translocation was observed in SPF morphine-
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tolerant mice (Fig. 3.3 A, B). As expected, morphine treatment failed to induce bacterial 
translocation in either GF or ABX mice (Fig. 3.3 A, B). However, when GF mice were 
reconstituted with the microbiota of naïve SPF mice, and then treated with morphine, 
bacterial translocation was observed (Fig. 3.3 C, D). In addition, when GF mice or ABX 
mice underwent FMT, the mice receiving morphine-tolerant microbiota showed 
significantly greater bacterial translocation than the mice receiving microbiota of 
saline-treated animals (Fig. 3.3 E, F). These studies suggest that morphine-induced gut 
integrity disruption and subsequent bacterial translocation is mediated by alterations in 
the gut microbiota. These results provide further evidence for the crucial role of 
morphine-induced dysbiosis in analgesic tolerance. 
 
4. Gut microbiota was fundamental to increase TLR2 and TLR4 expression in 
morphine tolerant mice.  
To further explore the characteristics of the translocated bacteria in the liver and MLN, 
we analyzed DNA isolated from the liver by gel-based PCR using the primers specific 
for gram-positive and gram-negative bacteria. We found both gram-positive and gram-
negative bacteria translocating to the liver in the morphine-tolerant animals (Fig. 3.4 
A). TLR2 and TLR4 are the major receptors that mediate the host’s response to gram-
positive and gram-negative bacteria, respectively. To determine the roles of TLR2 and 
TLR4 in morphine analgesic tolerance, we evaluated expression of these receptors on 
gut epithelial and immune cells. In morphine-tolerant animals, we found a significant 
increase in TLR2 and TLR4 expression in both gut epithelial cells (Fig. 3.4 B, C) and 
intraepithelial immune cells (Fig. 3.4 D, E). Furthermore, the expression of TLR2 and 
TLR4 was also significantly increased in circulating immune cells isolated from the 
blood of morphine-tolerant animals (Fig. 3.4 F, G). The expression levels of TLR2 and 
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TLR4 were not up-regulated by morphine treatment in ABX mice (Fig. 3.4 A, B, C and 
D). Surprisingly, in circulating immune cells, morphine increased TLR4 expression in 
GF mice (Fig. 3.4 G). However, in ABX mice, TLR4 expression on circulating immune 
cells was not altered by morphine (Fig. 3.4 G).  
 
After reconstituting the GF mice with the naïve microbiome of SPF mice, morphine 
treatment induced tolerance in these mice, and elevated TLR2 and TLR4 expression on 
gut epithelial and immune cells (Fig. 3.4 H, I, J, K, L, M). Moreover, transplantation of 
microbiota from morphine-tolerant mice alone was sufficient to enhance TLR2 and 
TLR4 protein expression in GF and ABX mice (Fig. 3.4 N, O, P, Q, R, S). These data 
suggest that TLR2 and TLR4 activation, as a consequence of dysbiosis and bacterial 
translocation, and the resulting induction of proinflammatory cytokines may be 
mediators of morphine analgesic tolerance. 
 
5. Neuroinflammation and small intestinal local inflammation required gut 
microbiota in morphine tolerant mice. 
Accumulating evidence implicates inflammation as a contributing factor in morphine-
induced analgesic tolerance. To further investigate the role of inflammatory cytokines 
in this process, animals were subjected to repeated morphine injections. In morphine-
tolerant animals, the protein levels of pro-inflammatory cytokines IL-6, IL-1β and 
TNF-α were measured in the liver, MLN, and brain by enzyme-linked immunosorbent 
assay (ELISA). Additionally, messenger RNA levels of these cytokines were also 
determined in the spinal cords and intestines. Morphine-tolerant animals displayed 
significantly elevated levels of these cytokines in all tissues examined. However, 
morphine administration to GF and ABX mice showed less inflammatory response (Fig. 
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3.5 A, B, C, D, E, F, Table 1). GF mice receiving naïve SPF microbiota developed 
analgesic tolerance and displayed higher expressions of these cytokines following 
morphine treatment (Fig. 3.5 G, H, I, J, K, L, Table 2). FMT of the gut microbiota from 
morphine-tolerant mice into GF and ABX recipients resulted in increased expression 
of these cytokines. (Fig. 3.5 M, N, O, P, Q, R, Table 3). Together, these studies 
demonstrate that alteration in microbial compositions disrupted gut integrity, facilitated 
bacterial translocation, regulated TLR expressions and activation, and exacerbated 
inflammation, all contributing to morphine tolerance. 
 
6. TLR2KO and TLR4KO mice exhibited less gut leakage, fewer bacterial 
translocation and diminished inflammation after chronic morphine treatment. 
The TLR2KO and TLR4KO mice, as previously described, exhibited attenuated 
morphine tolerance after 15mg/kg morphine twice daily administration. Compared to 
WT morphine-treated mice, both TLR2KO and TLR4KO mice displayed less impaired 
gut integrity (Fig. 3.6 A) and lower bacterial translocation (Fig. 3.6 B, C) after 
morphine treatment. Repeated morphine injections into TLR2KO and TLR4KO mice 
induced less inflammation than equivalent injections into WT mice (Fig. 3.6 D, E, F, 
G, H, I, Table 4).  
 
7. IL-6KO mice exhibited less gut morphological changes and bacterial 
translocation after chronic morphine treatment.  
The IL-6KO mice, which have attenuated morphine tolerance as previously described, 
have alleviated gut histological damage (Fig. 3.7 A) and bacterial translocation (Fig. 
3.7 B, C) compared to WT control. 
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8. VSL#3 probiotics attenuated chronic morphine-induced morphological 
damage and following gut leakage and bacterial translocation. 
As previously described, the VSL#3-treated mice exhibited less tolerance than sham 
mice after chronic morphine injection. The VLS#3 probiotics restored morphine-
induced dysbiosis, especially reinstalling the abundance of Lactobacillaceae and 
Bifidobacteriaceae. Comparing with the morphine-treated mice, the gut histology 
showed less immune cell infiltration and gut epithelial damage in VSL#3 + morphine-
treated mice (Fig. 3.8 A).  Morphine-induced gut permeability (Fig. 3.8 B) and systemic 
bacterial translocation into liver and MLN (Fig. 3.8 C, D) were rescued using probiotics 
treatment. 
 
9. VSL#3 probiotics attenuated chronic morphine induced TLR2 and TLR4 
expression increase. 
Furthermore, morphine tolerance-induced increases in TLR2 and TLR4 expression on 
the gut epithelia, gut and systemic immune cells (Fig. 3.9 A, B, C, D, E, F) which were 
also ameliorated by probiotics pre-treatment.  
 
10.  VSL#3 probiotics attenuated chronic morphine-induced intestinal and spinal 
cord inflammation. 
The morphine-induced elevated proinflammatory cytokines IL-6 (Fig. 3.10 A, B), IL-
1β (Fig. 3.10 C, D) and TNF-α (Fig. 3.10 E, F) in intestine and spinal cord, which were 
also ameliorated by probiotics pre-treatment. These data clearly support the use of 
probiotics as an adjunct therapy in patients using opioids for pain management. 
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DISCUSSION 
In the present study, different mouse models were used to demonstrate that the gut 
microbiota plays an essential role in TLR2 and TLR4 expression and activation, gut 
epithelial integrity, bacterial translocation, inflammation, therefore contributing to 
morphine tolerance. We show that morphine-induced dysbiosis promotes gut 
permeability and bacterial translocation. The translocated bacteria and bacterial 
components circulate into system, activate systemic TLR2 and TLR4 on the immune 
cells and assist inflammation, therefore generating and maintaining morphine analgesic 
tolerance. To establish cause-effect relationship, both GF mice and an antibiotic 
bacterial depletion strategy were used. Both in GF and ABX treated mice morphine 
treatment did not result in significant bacterial translocation. Hence no inflammation 
was generated to facilitate morphine tolerance. However, when morphine-induced 
dysbiosis was restored by probiotics treatment, less bacterial translocation occurred, 
and less inflammation were detected in both intestine and spinal cord. 
 
In the GF mice, we observed analgesic tolerance with less neuroinflammation. One 
explanation is that there are no bacteria translocated from gut lumen after chronic 
morphine treatment. Therefore, TLR2 and TLR4 are not activated and less pro-
inflammatory cytokines are generated that contribute to neuroinflammation. Another 
explanation is that proinflammatory gene expression is attenuated in GF mice because 
of their abnormal microglial cells(170). Although GF mice have more microglial cells, 
they are defective in GF mice in response to bacterial or viral challenge, indicating that 
the microbiota is required to respond to pathogenic infection in both the periphery and 
the central nervous system. These microglia impairment could be restored by 
microbiota or SCFA(145)(170). Antibiotic-treated SPF mice also exhibit immature 
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microglia similar to GF mice(170). Although we have not detected microglial activation 
in morphine-treated GF and ABX mice, modulation of microglia function in GF mice 
and in ABX treated mice may explain the decrease neuroinflammation that is observed 
in GF and ABX-treated mice following chronic morphine challenge. In addition, 
Fagundes et al (2008) demonstrated diminished inflammatory hypernociception in GF 
mice after carrageenan challenge. GF mice also displayed reduced perception of pain 
after TNF-α and IL1-β inflammatory stimulation. These findings implicated an 
important role of commensal microbiota for the host in the perception of pain(144).    
 
Furthermore, GF mice exhibited increased adult hippocampal neurogenesis(171). 
Chronic morphine treatment had negative impact on neuronal differentiation, neurite 
outgrowth and survival of adult hippocampal neural progenitor cells in conventionally 
raised mice(172). It implies that GF mice may have more hippocampal neurogenesis to 
compensate for the adverse effects of morphine on hippocampal neurons, therefore 
displaying less morphine tolerance. Moreover, GF mice were found to have decreased 
levels of N-methyl-D-aspartate (NMDA) receptors, specifically NR1 and NR2 
subunits(173)(174), whose expression upregulation and activation have been suggested 
to promote morphine tolerance(175). In addition, one of the key regulators of morphine 
tolerance is BDNF, which was found to be less in the cortex and hippocampus of GF 
animals compared with control(174).  Taken together, it has been demonstrated that the 
gut microbiota is essential for optimal brain functioning which are evident from GF 
mice studies. Thus, alteration of these factors besides inflammation have to be taken 
into consideration when interpreting data on delineating mechanisms underlying 
morphine-induced analgesic tolerance in GF mice.  
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It has been reported that GF and ABX animals have reduced expression of TLR1 and 
TLR2, but similar expression of TLR4 and TLR6 in the gut. The recolonization of gut 
microbiota into GF mice and ABX mice augment the expression of TLR1 and 
TLR2(176). In our chronic morphine treatment model, TLR2 and TLR4 expression on 
both gut epithelial cells and immune cells were increased. As a consequence, morphine-
induced bacterial translocation was observed leading to activated systemic immune 
cells. However, these phenomena were not obvious in GF and ABX animals. The 
increased TLR2 and TLR4 expression and activation are recapitulated after GF mice 
were recolonized with microbiota from morphine-treated mice. It indicates that the 
activation and higher expression of TLR2 and TLR4 is due to morphine-induced 
dysbiosis. In addition, the GF mice have reduced IgA secretion, and fewer and smaller 
Peyer’s patches(145). In the cirrhosis model, the GF mice had less IL-1β and TNFα in 
the serum compared to conventional cirrhotic mice(142). In our chronic morphine 
model, IL-6, IL-1β and TNFα were attenuated in both small intestine and spinal cord 
in GF mice. Reduced proinflammatory cytokines might explain decrease in morphine 
tolerance in these mice. 
 
Our studies using FMT provided the most convincing evidence for the role of 
microbiota in gut-immune-CNS signaling. In our studies, we used both GF mouse 
model and ABX mouse model. In both FMT models, we demonstrated the microflora 
alteration was sufficient to initiate detrimental outcomes of chronic morphine treatment, 
thus contributing to morphine-induced analgesic tolerance. Furthermore, daily gavage 
of saline microbiome significantly alleviated the development of morphine tolerance. 
It implied that symbiotic bacteria can protect against morphine-induced dysbiosis, thus 
maintaining CNS health and proper behavior. In addition, we found that sustained lower 
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expression of epithelial TLR2 and TLR4 in axenic and antibiotic-treated mice 
subsequently recovered in saline-microbiota-recolonized mice, and pathogenically 
enhanced in morphine-microbiota-recolonized mice and saline-microbiota-recolonized 
mice with chronic morphine treatment, suggesting the microflora regulate host behavior.  
 
The breakdown of gut homeostasis caused by gut dysbiosis, and the consequently 
increased intestinal permeability and bacterial translocation, was increasingly 
considered to be the ultimate source of the systemic immune activation and 
neurological disturbances. The “leaky gut” and enteric bacterial translocation were 
consistently observed in autoimmune diseases such as type 1 diabetes, inflammatory 
bowel disease, neurobehavioral changes in obesity, chronic fatigue syndrome, stress, 
Autism Spectrum Disorder, frailty, schizophrenia, Alzheimer’s disease and brain 
dysfunction after sepsis(177)(178). Dysbiosis-induced production and secretion of 
compounds such as LPS and LTA reduced the tightness of the intestinal barrier, 
facilitating the contact of the pathogenic bacteria with submucosal lymphoid tissue. As 
a result, systemic inflammatory reactions occurred, which initiated neuroinflammation 
and, ultimately pathophysiology of these diseases. Thus, targeting intestinal integrity 
could provide new therapeutic possibilities of neuroinflammation and morphine-
induced analgesic tolerance. 
 
Recent studies have shown the benefits of probiotics as a means to restore and maintain 
health in diseased states such as allergic disease, diarrhea, irritable bowel disease, 
Alzheimer’s disease, anxiety, stress and depression(179)(180)(181)(182)(183). A 
recent report showed an increase in OPRM1 expression in human HT-29 epithelial cells 
following treatment with Lactobacillus (especially L. acidophilus NCFM)(184). These 
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studies further suggested that commensal bacteria can control the transmission of 
nociceptive information of the intestinal nervous system through OPRM1. It is likely 
that loss of these commensals, along with reduced expression of OPRM1 on epithelial 
cells, may contribute to reduced antinociceptive signals and heightened pain. In 
addition, VSL#3 probiotics have been shown to inhibit disease-associated cytokines 
IFN-g, IL-17, and IL-6 while increasing anti-inflammatory cytokines TGF-b, IL-10 and 
IL-4 in EAE(167). Furthermore, VSL#3 probiotics were reported to ameliorate age-
related deficits and reverse the effects of genes associated with aging(185). Furthermore, 
Zareie et al. (2006) also found that pretreatment of Lactobacillus helveticus and 
Lactobacillus rhamnosus prevented mucosal barrier dysfunction and bacterial 
translocation in chronic stress model, indicating probiotics could abrogate chronic 
psychological stress-induced intestinal abnormalities(183). Consistent with these 
studies, our studies found that decreases in Lactobacillus and Bifidobacterium play a 
crucial role in gut inflammation and are thus implicated in morphine tolerance. Our 
studies support the protective effect of probiotics on reinstating morphine effectiveness 
through the gut-brain axis in a morphine-tolerant model. 
 
Previous literature showed that increased TLR2 and TLR4 mRNA and protein level on 
microglia in CNS after morphine exposure(163). It is noteworthy that TLR4 activation 
disrupted extracellular glutamate homeostasis between synapse owing to decreased 
glutamate uptake by astrocyte glutamate transporters, creating an environment of 
neuroexcitability(155). In addition, opioid-induced astrocyte and microglial activation 
leads to the release of many inflammatory cytokines not limited to IL-6, IL-1b, and 
TNFa, interleukins, interferons, monocyte chemotactic protein-1, CCL2, CCL3, CCL5, 
CXCL10, inducible nitric oxide synthase(79). These inflammatory molecules can 
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induce the production of a variety of neuroexcitatory substances such as nitric oxide, 
prostaglandin E2, and reactive oxygen species that modulate neuronal functioning(79).  
It has been previously shown that blockade of TLR4 attenuates the development of 
morphine tolerance by down-regulation of glial GLT-1 and GLAST glutamate 
transporters and proinflammatory cytokines production(186). TLR2 on microglial cells 
also contribute to morphine withdrawal. It was reported mice deficient in TLR2 
inhibited morphine-induced microglia activation and dependence(187). However, the 
role of peripheral TLR2 and TLR4 function in morphine induced analgesic tolerance 
has been not reported. Previously in our lab, we demonstrated that the increased 
expressions of TLR2 and TLR4 on gut epithelia by morphine is involved in disrupting 
tight junctions, leading to leaky barrier and allowing the ingress of bacteria(59). In the 
present study, the expression of TLR2 and TLR4 were also found to be elevated in gut 
immune cells and systemic leukocytes after morphine administration. Moreover, 
morphine-induced bacterial alteration is sufficient to enhance TLR2 and TLR4 
expression and activate TLR2 and TLR4 signaling pathway. The presence of bacteria 
in liver and MLN induced increase in systemic TLR2 and TLR4 expression and 
activation of these receptors lead to the production of proinflammatory cytokines IL-6, 
IL-1β and TNF-α.  
 
Interestingly, in our previous studies and also in the current study showed that TLR2KO 
and TLR4KO mice were protected from microbial shift by morphine treatment. 
Attenuation of analgesic tolerance was detected in both TLR2KO and TLR4KO mice. 
Our lab has shown that lipid metabolites, especially bile acids, exhibited significant 
changes after morphine treatment. One of the major observations was a significantly 
higher level of cholesterol and its derivative coprostanol in morphine-treated WT mice. 
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However, the basal cholesterol levels in TLR2KO mice were significantly lower than 
their WT counterparts(118). On the other hand, concentrations of the host-derived 
primary and microbe-converted secondary bile acids were seen to diminish 
significantly in the feces of WT morphine-treated mice. However, the morphine-
mediated changes were completely abolished in the TLR2KO animals(118). Therefore, 
we speculated that indigenous microflora regulates its host through modulating lipid 
metabolism, thus having an effect on morphine-induced behavior changes. However, 
how TLR2 modulation of lipid metabolism confers a protective role in morphine-
induced tolerance needs further investigation. 
 
In conclusion, the murine model of morphine analgesic tolerance showed an important 
link between the neuroinflammation and gut microbiota. Notably, the pan-antibiotic-
treated and GF mice had ameliorated neuroinflammation, whereas microbial re-
colonization with morphine-treated mice restored these functions. In our present study, 
we speculated that morphine-induced inflammation is a consequence of gut-host 
interaction. Changes in the composition of the gut microbiome, termed gut dysbiosis, 
leads to the breakdown of immune homeostasis in the intestinal immune system, which 
in turn induce distal abnormalities in the systemic immune and inflammatory pathways 
and thus playing a significant role in the development of morphine tolerance.  
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Figure 3.1 Morphine and morphine-induced dysbiosis cause gut epithelial damage.  (A-
F) SPF, GF and pan-antibiotics-pretreated SPF (SPF/ABX) mice were treated with 
saline or chronic morphine for 8 days. (G-H) GF mice were FMT with naïve microbiota, 
then treated with chronic morphine. (I-L) The GF or SPF/ABX mice were transplanted 
with gut microbiota from either saline or morphine-treated mice. Representative H&E 
stained section of mouse ileum. Scale bar: 100μm. WT and ABX mice: nSPF=10, nGF=3. 
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Figure 3.2 Chronic morphine treatment and morphine-induced microbiota alteration 
induce gut permeability. (A, B) Representative images and summary of fluorescein 
isothiocyanate (FITC)-dextran fluorescent signal distribution in mice. n=6-11. 
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Figure 3.3 Morphine-induced dysbiosis is responsible for bacterial translocation. (A, 
B) Bacterial colony forming unit (CFU) in liver and MLN homogenates of GF and SPF 
mice. nSPF=10-20; nGF=3. Data were analyzed by one-way ANOVA followed by 
Bonferroni’s multiple comparisons test. (C, D) CFU from GF mice reconstituted with 
normal gut microbiota and treated with either morphine or saline. nGF = 3. (E, F) CFU 
from GF mice and ABX-treated SPF mice received gut microbiota either from saline 
or morphine tolerant- donors. nGF = 3, nSPF/ABX = 10-12. Data were analyzed by 
student’s t-test. *, p<0.05; **, p<0.01; ***, p<0.001, ****, p<0.0001. Mean ± SD. 
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Fig. 3.4: Morphine regulates gut and systemic TLR2 and TLR4 expression through gut 
microbiome. (A) The 355-bp amplicon is specific for gram-positive bacteria and the 
985-bp amplicon is specific for gram-negative bacteria. Lane 1 is DNA ladder. Lane 2-
9 is bacteria DNA from liver homogenates from saline-treated mice; lane 10-17 is 
bacteria DNA from liver homogenates from morphine-treated mice; lane 18 is C. 
Rodentium for gram-negative bacteria as a positive control; lane 19 is E. Faecalis for 
gram-positive bacteria as a positive control; lane 20 is purified water for negative 
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control. (B-G) The up-regulation of TLR2 and TLR4 expression by morphine was 
suppressed in GF and ABX mice. nGF=3; nSPF=12-15. (H-M) Morphine induced TLR2 
and TLR4 expression in GF mice following gavaging with naïve mouse microbiota. 
nGF=3. (B-G) Data were analyzed by one-way ANOVA followed by Bonferroni’s 
multiple comparisons test. (N-S) The microbiota FMT from morphine-tolerant mice 
alone increased TLR2 and TLR4 expression in GF and ABX mice. nGF=3. nABX=5. 
Two-tailed student’s t-test was used for statistical analysis.  
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Fig.  3.5: Gut microbiome is essential for morphine-induced chronic systemic 
inflammation. (A-F) IL-6, TNFa, and IL-1b expression in morphine-treated GF and 
ABX mice was reduced when compared to WT controls. nGF=3, nSPF=10-17. (G-L) 
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Morphine effect on the expression of proinflammatory cytokines was restored after gut 
microbiota was reconstituted in GF mice. nGF=3. (A-F) Data were analyzed using one-
way ANOVA followed by Bonferroni’s multiple comparisons test. (G-L) GF and ABX 
mice were gavaged with microbiota from either saline or morphine-tolerant mice. 
nGF=3; nSPF/ABX=13-15. Significance was tested by two-tailed student’s t-test. (M-R) 
GF and ABX mice were gavaged with microbiota from either saline or morphine-
tolerant mice. nGF=3; nSPF/ABX=13-15. Significance was tested by two-tailed 
student’s t-test. 
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Fig. 3.6 Gut permeability, bacterial translocation and pro-inflammatory cytokine 
expression are attenuated in TLR2KO and TLR4KO mice compared to WT controls. 
(A) (i) Representative images and (ii) summary of fluorescent signal distribution in 
morphine-treated WT, TLR2KO and TLR4KO mice. n=6-10. (B, C) Visualization of 
Bacterial colonies in blood agar plates from liver and MLN homogenates. (D-I) IL-6, 
TNF-a, and IL-1b expressions were detected in WT, TLR2KO and TLR4KO mice. 
n=8-16.  
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Fig. 3.7 Gut morphological damage and bacterial translocation are alleviated in IL-
6KO mice. (A) Representative H&E stained intestinal sections from morphine treated- 
WT and IL-6KO mice. n=6. (B, C) The liver and MLN homogenates from WT and 
IL6KO mice were plated on blood agar plates overnight. Bacterial colonies were 
counted (colony forming unit). n=6-9. One-way ANOVA followed by Bonferroni’s 
multiple comparisons test was used for statistical analysis. *, p<0.05; **, p<0.01; 
***p<0.001; ****p<0.0001. Mean ± SD. 
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Fig. 3.8 Probiotics VSL#3 pre-treatment reverses morphine-induced gut pathology. (A) 
Representative H&E stained intestinal sections from different treatment groups. n=6-
10.  (B) (i) Representative figure of florescent signal distribution and (ii) summary of 
serum fluorescein isothiocyanate-dextran concentration from different treatment 
groups. n=6-10. (C, D) CFU from liver homogenate of each mouse in different 
treatment groups. n=6-20. 
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Fig. 3.9 Probiotics pre-treatment inhibits TLR2 and TLR4 up-regulation by morphine 
on epithelial and immune cells. n=11-14. The results were analyzed by one-way 
ANOVA followed by Bonferroni’s multiple comparisons test. *, p<0.05; **, p<0.01; 
***, p<0.001; ****p < 0.0001. Mean ± SD. 
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Fig. 3.10 Probiotics pretreatment attenuated morphine-induced proinflammatory 
cytokines expression. (A-F) RT-PCR of the IL-6, TNF-a, and IL-1b gene expression. 
n=9-19. One-way ANOVA followed by Bonferroni’s multiple comparisons test was 
used to analyze the data. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p< 0.0001. Mean 
± SD. 
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Table 3.1: Inflammation induced by morphine tolerance was alleviated in SPF/ABX 
and GF mice.  
Mice  SPF mice GF mice 
Tissue  Treatment 
 Pro-
inflam
matory 
cytokin
es 
(pg/µg) 
Water + 
Saline 
ABX + 
Saline 
Water + 
Morphine 
ABX + 
Morphine 
Saline Morphine 
Brain IL-6 0.0755±0
.0293*** 
0.0583±0
.0364*** 
0.3743±0.1
707 
0.1499±0.08
26** 
0.0088
±0.005
5** 
0.039±0.00
19** 
 IL-1b 0.0721±0
.0616*** 
0.0463±0
.0315***
* 
0.3921±0.2
102 
0.0789±0.05
41*** 
0.0194
±0.007
8**** 
0.0252±0.0
098**** 
 TNFa 0.1222±0
.0540***
* 
0.1298±0
.0439***
* 
0.4263±0.1
091 
0.1790±0.09
49**** 
0.0188
±0.003
6**** 
0.0234±0.0
059**** 
Liver IL-6 0.0420±0
.0263*** 
0.0075±0
.0074***
* 
0.1112±0.0
552 
0.1076±0.07
81*** 
0.0301
±0.020
6** 
0.0393±0.0
322* 
 IL-1b 0.0373±0
.0310** 
0.0241±0
.0169*** 
0.1180±0.0
463 
0.0621±0.04
96* 
0.0204
±0.028
6 
0.0442±0.0
365 
 TNFa 0.0748±0
.0388** 
0.0422±0
.0324***
* 
0.2804±0.0
1909 
0.1252±0.12
52*** 
0.058.8
±0.034
6** 
0.1138±0.0
765* 
MLN IL-6 0.0158±0
.0126***
* 
0.0682±0
.065.6**
** 
0.3625±0.1
913 
0.0327±0.03
53**** 
0.0204
±0.004
4*** 
0.0123±0.0
035*** 
 IL-1b 0.0402±0
.0183*** 
0.0404±0
.0258***
* 
0.1668±0.0
598 
0.0589±0.04
55**** 
0.0404
±0.005
5** 
0.0272±0.0
055** 
 TNFa 0.0440±0
.0348*** 
0.0382±0
.0205***
* 
0.1393±0.0
643 
0.028.1±0.0
226**** 
0.0364
±0.008
8*** 
0.0388±0.0
081*** 
IL-6, IL-1β and TNFα concentrations in the homogenates of brain, liver and MLN from 
SPF and GF mice were determined by ELISA. nWT=6-10, nGF=3. Data show Mean±SD. 
*, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001. Water+Morphine treatment 
group was used for statistical comparison. Significance was calculated by one-way 
ANOVA followed by Bonferroni’s multiple comparisons test. 
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Table 3.2: After FMT with naïve SPF microbiota, GF mice displayed higher 
expression of cytokines following morphine treatment.  
Mice  GF mice 
  Treatment 
 Pro-inflammatory cytokines (pg/µg) Saline microbiome 
-Saline 
Saline microbiome 
-Morphine 
Brain IL-6 0.0197±0.0107 0.1349±0.0694* 
 IL-1b 0.0452±0.0164 0.2992±0.1081* 
 TNFa 0.0238±0.0052 0.3132±0.1444* 
Liver IL-6 0.0566±0.0098 0.4967±0.2318* 
 IL-1b 0.0756±0.0635 0.8375±0.4089* 
 TNFa 0.1071±19.8 0.654±0.3056* 
MLN IL-6 0.0483±0.0310 0.3020±0.0945* 
 IL-1b 0.1094±0.0724 0.5588±0.2297* 
 TNFa 0.1283±0.0656 0.2132±0.0609*** 
After GF mice were transplanted with control microbiome (FMT), inflammatory 
cytokine levels were measured and compared to morphine-treated mice. Data show 
Mean ± SD. nGF=3. The data were analyzed by one-way ANOVA followed by 
Bonferroni’s multiple comparisons test. *, p<0.05; ***, p<0.001. 
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Table 3.3: Morphine microbiome FMT alone induced inflammation without exposure 
to morphine.  
Mice  SPF mice GF mice 
  Treatment 
 Pro-
inflammator
y cytokines 
(pg/µg) 
Saline 
microbiome 
Morphine 
microbiome 
Saline 
microbiome 
Morphine 
microbiome 
Brai
n 
IL-6 0.0164±0.0102 0.1561±0.0612**** 0.0187±0.011
5 
0.1893±0.0754# 
 IL-1b 0.0461±0.0221 0.1789±0.0657**** 0.0465±0.032
7 
0.4851±0.1374## 
 TNFa 0.0508±0.0290 0.3148±0.095.2***
* 
0.0721±0.061
1 
0.3945±0.0541## 
Live
r 
IL-6 0.0304±0.0197 0.2281±0.1279*** 0.0359±0.008
1 
0.2868±0.1354# 
 IL-1b 0.026.9±0.013
8 
0.3248±0.1191**** 0.0671±0.029
3 
0.3521±0.1260# 
 TNFa 0.0369±0.0109 0.3241±0.1146**** 0.0758±0.016
5 
0.03633±0.1558
# 
ML
N 
IL-6 0.0526±0.0329 0.292.2±0.1315***
* 
0.0204±0.007
9 
0.1493±0.0219##
# 
 IL-1b 0.1272±0.1119 0.7111±0.3607**** 0.0646±0.030
8 
0.1653±0.0255# 
 TNFa 0.0462±0.0279 0.5247±0.2448**** 0.0531±0.011
6 
0.2828±0.0402##
# 
Saline microbiome group (FMT) was compared with morphine microbiome (FMT) in 
either SPF or GF mice. Data show Mean ± SD. nSPF=10, nGF=3. The data were analyzed 
by one-way ANOVA followed by Bonferroni’s multiple comparisons test. *, #, p<0.05; 
**, ##, p<0.01; ***, ####, p<0.001; ****, ####, p<0.0001 
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Table 3.4: Inflammation induced by morphine tolerance was attenuated in TLR2KO 
and TLR4KO mice.  
Mice  WT mice TLR2KO mice TLR4KO mice 
Tissue  Treatment 
 Pro-
inflammatory 
cytokines 
(pg/µg) 
Saline Morphine Saline Morphine Saline Morphine 
Brain IL-6 0.0192
±0.009
1**** 
0.1992±0.0
638 
0.0178±0
.0041***
* 
0.0210±0.0
079**** 
0.0112
±0.005
5**** 
0.0159±0.
0053**** 
 IL-1b 0.0403
±0.010
5**** 
0.2445±0.1
150 
0.0464±0
.0135***
* 
0.0596±0.0
297**** 
0.0200
±0.011
9**** 
0.0376±0.
0310**** 
 TNFa 0.0364
±0.013
4**** 
0.3071±0.0
333 
0.0430±0
.0173 
**** 
0.0555±0.0
269**** 
0.0070
±0.004
9**** 
0.0476±0.
0168**** 
Liver IL-6 0.0110
±0.004
4**** 
0.0623±0.0
315 
0.0114±0
.0039***
* 
0.0180±0.0
093**** 
0.0136
±0.006
6**** 
0.0236±0.
0145*** 
 IL-1b 0.0351
±0.017
5**** 
0.1515±0.0
490 
0.0160±0
.0101***
* 
0.0209±0.0
063**** 
0.0298
±0.050
2**** 
0.0873±0.
0520 
 TNFa 0.0217
±0.018
0*** 
0.0873±0.0
467 
0.0080±0
.0029***
* 
0.0291±0.0
215*** 
0.0300
±0.028
3**** 
0.0500±0.
0221 
MLN IL-6 0.0177
±0.006
7**** 
0.1172±0.0
493 
0.0069±0
.0051***
* 
0.0322±0.0
189**** 
0.0101
±0.005
5**** 
0.0189±0.
0114**** 
 IL-1b 0.0170
±0.005
5**** 
0.0959±0.0
217 
0.0182±0
.0089***
* 
0.0459±0.0
319** 
0.0187
±0.010
1**** 
0.0682±0.
0526* 
 TNFa 0.0267
±0.015
8**** 
0.2458±0.1
212 
0.0147±0
.0160***
* 
0.0542±0.0
310**** 
0.0406
±0.077
5**** 
0.0473±0.
0196**** 
Inflammatory cytokine levels were measured in tissue homogenates. Data are 
represented as Mean ± SD. nWT=7-10, nTLR2KO=8-12, nTLR4KO=8-12. One-way ANOVA 
followed by Bonferroni’s multiple comparisons test was used for statistical analyses. *, 
p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001. 
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Table 5: Probiotics pre-treatment attenuated morphine tolerance-induced 
inflammation.  
Tissu
e 
 Treatment 
 Pro-
inflammato
ry 
cytokines 
(pg/µg) 
Sham + Saline  VSL#3 + Saline Sham + 
Morphine 
VSL#3 + 
Morphine 
Brain IL-6 0.0202±0.0094**
** 
0.239±0.0075***
* 
0.1680±0.08
96 
0.0502±0.0725**
** 
 IL-1b 0.0477±0.0119**
** 
0.0389±0.0176**
** 
0.2953±0.10
89 
0.1161±0.0980**
** 
 TNFa 0.0343±0.0178**
** 
0.0313±0.0160**
** 
0.1969±0.08
29 
0.0622±0.0539**
** 
Liver IL-6 0.0144±0.0118** 0.0099±0.0039**
* 
0.0438±0.02
38 
0.0228±0.0093* 
 IL-1b 0.0981±0.0365**
** 
0.0851±0.0236**
** 
0.4084±0.13
84 
0.1422±0.1382**
** 
 TNFa 0.0271±0.0229**
** 
0.0256±0.0160**
** 
0.1026±0.03
05 
0.0994±0.0723**
# 
MLN IL-6 0.0196±0.0114**
** 
0.0331±0.0314**
** 
0.1110±0.06
45 
0.0279±0.0132**
** 
 IL-1b 0.0280±0.0118**
* 
0.0281±0.0134**
* 
0.1212±0.04
08 
0.0739±0.0499* 
 TNFa 0.0318±0.0236**
* 
0.0345±0.0212**
* 
0.1306±0.06
26 
0.0579±0.0325** 
Cytokine levels from control treated animals (gavaged with water) and morphine 
treated animals were compared to all the other treatment groups. Data show Mean ± 
SD. n=5-12. One-way ANOVA followed by Bonferroni’s multiple comparisons test 
was used. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001. Cytokine levels from 
control treated animals (gavaged with water) and treated with saline were compared to 
VSL#3 + Morphine.  #p<0.05.   
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CHAPTER 4 
THE LIMITATIONS OF THE STUDY AND FUTURE PLANS 
In this study, we focused on the contribution of peripheral mechanisms to morphine-
induced tolerance. We discovered that microbial dysbiosis, bacterial translocation, 
intestinal and systemic TLR2 and TLR4 activation, and inflammation as mediators of 
morphine analgesic tolerance. However, there are some limitations in our studies in 
their current form.  
 
First of all, we emphasized cytokines, which augmented by morphine-induced 
dysbiosis, contributing to neuroinflammation and morphine tolerance. However, the 
morphine tolerance involves multiple mechanisms including OPRM1 signaling 
pathway, NMDA receptor system, morphine pharmacokinetics/pharmacodynamic, 
activation of microglia and astrocytes, interplay of different opioid receptors, other than 
neuroinflammation and peripheral inflammation. Our studies did not investigate 
whether manipulation of microbiota influences OPRM1 expression and its signaling 
pathway. As mentioned previously, L. acidophilus and L. salivarius induced an 
increased expression of OPRM1 mRNA in epithelial cells(184).  It is expected that 
VSL#3 administration might increase OPRM1 expression in the gut (either epithelial 
cells or immune cells), and more morphine molecules could bind to the receptors, thus 
attenuating morphine tolerance. The FMT from morphine tolerant mice might decrease 
OPRM1 expression, thus accelerating morphine tolerance.  
 
In our studies, we focused on the role of gut microbiota in morphine analgesic tolerance. 
The gut microbiota in TLR2KO mice were found to be resistant to chronic morphine 
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treatment. To further prove the role of gut microbiota on morphine tolerance, we plan 
on performing FMT of microbiota from TLR2KO mice or WT mice into GF mice and 
detect the generation of morphine tolerance. We hypothesize that chronic morphine 
treatment will not alter the microbiota from TLR2KO mice in GF mice, thus displaying 
less tolerance than the GF mice FMT with WT mouse microbiota. These experiments 
will allow us to identify bacterial communities that confer resistance to morphine-
induced microbial change. 
 
A number of studies associate disruption in commensal gut microbiota on CNS and 
behavioral changes mediated through vagus nerve, bacterial metabolites, and hormone, 
in addition to cytokines. The vagal system is crucial to gut-brain axis. L. rhamnosus 
(JB-1) reduced stress-induced corticosterone and anxiety- and depression-related 
behavior through modulating GABA receptors, but these changes were abolished in 
vagotomized mice(188). On the contrary, another study showed that when mice were 
infected with T. muris, the vagotomized mice displayed same anxiety-like behavior as 
sham infected mice without vagotomy(189). These findings indicate that vagal system 
might be one of the pathways how dysbiosis or gut inflammation affects behavior. 
There are limited studies investigated vagal nerve involvement in morphine tolerant 
rodent models. The limitations of our studies are that we have not studied if morphine-
induced dysbiosis has an impact on vagal nerve function and its contribution to 
morphine tolerance.  
 
Our studies suggest that chronic morphine treatment depletes beneficial bacteria such 
as Lactobacillus and Bifidobacteria and facilitates the expansion of pathobiome. 
However, our analysis is limited to the genus level because our sequencing method is 
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based on 16S rRNA with a single marker gene. The bacterial species in Lactobacillus 
and Bifidobacteria genus, which have neuroprotective properties against morphine-
induced neuroinflammation and analgesic tolerance, have not been exploited. In 
addition, our studies discuss the role of dysbiosis in regulation of gastrointestinal 
inflammation and its impact on neuroinflammation in morphine tolerant model. 
However, we have not systematically analyzed the functional metagenomics of the 
altered microbiome in detail. The analysis of functional profile of the microbial 
communities will determine how bacterial gene content regulates the host. Preliminary 
studies have shown chronic morphine treatment increased functional gene profile 
related to cell motility, human diseases such as cancer, neurodegenerative disease and 
cardiovascular disease and decreased genes related to metabolism of terpenoids and 
polyketides, nucleotide metabolism, amino acid metabolism, xenobiotics 
biodegradation and metabolism and carbohydrate metabolism (Fig. 4A). The VSL#3, 
which replenished the missing bacteria, rebalanced these functions (Fig. 4B). However, 
the single marker gene of 16S rRNA is susceptible to provide us biased results. 
 
To solve these two potential problems, whole-metagenome shotgun sequencing should 
be applied. The non-targeted sequencing of DNA fragments will decipher taxonomy to 
species level or even strain level. Analyses based on shotgun deep sequencing will 
provide direct and precise functional inference. Furthermore, to further prove the 
predictive chronic morphine-induced alterations, the meta-metabolome analysis such 
as liquid chromatography-mass spectrometry will be carried out.  
 
In addition, we suggested that TLR2 and TLR4 are components of the gut-brain axis 
that contribute to morphine tolerance. However, the roles of TLR2 and TLR4 in 
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morphine analgesic tolerance have not been fully delineated. Previous studies showed 
that TLR2 and TLR4 expression were upregulated in microglia and gut epithelial 
cells(59)(163). TLR2 and TLR4 protect morphine-induced gut epithelial tight junction 
disruption in a MLCK-dependent manner(59). In our studies, TLR2KO and TLR4KO 
mice have protective properties against neuroinflammation following chronic morphine 
challenge. TLR2 and TLR4 have been shown to play critical roles in morphine 
dependence, withdrawal, and tolerance. However, there are limited studies on the 
interaction between TLR2/4 and OPRM1 signaling pathways. Studies have shown that 
both chronic morphine treatment and activation of TLR2/4 share the downstream 
signaling pathways of MAPK, NF-κB, AP-1 and CREB(102)(190). We hypothesize 
that morphine activates OPRM1 and might increase the expression or activate TLR2/4 
downstream pathways through their shared signaling pathway. The activation of 
TLR2/4 initiates the production of pro-inflammatory cytokines. Proinflammatory 
cytokines such as IL-6 also share MAPK signaling pathway with OPRM1 signaling 
pathways(191). Additionally, studies have shown that morphine tolerance was 
attenuated by inhibiting p38 MAPK in activated spinal microglia(158). The interaction 
among all the signaling pathways exacerbated chronic morphine-induced adverse 
effects. Additionally, the PU.1 that is activated by TLR4 signaling was found to bind 
to the promoter of OPRM1 gene and transcriptionally regulate its expression(191). We 
hypothesize TLR2/4 or IL-6 might regulate PU.1 binding to OPRM1 gene to affect the 
OPRM1 expression and activation. We could answer this question by comparing 
OPRM1 expression in WT mice and TLR2KO, TLR4KO and IL-6KO mice. Moreover, 
cytokines or chemokines might regulate the neurotransmitters and their receptors that 
could play a central role in morphine tolerance. It is hypothesized that IL-6 might 
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increase the intracellular calcium responses to NMDA by increasing intracellular 
calcium signals, therefore sensitizing neuronal response to xenobiotics(192).  
 
Our studies have shown an increase in TLR2 and TLR4 expression on immune cells 
and gut epithelial cells. Therefore, morphine tolerance attenuation is observed in 
TLR2KO and TLR4KO mice. TLR2/4 expression on which cells contribute to 
morphine tolerance are of great interest for the development of tolerance. To further 
explore these questions, two models can be used.  
 
One model is to use bone marrow transplantation. There is evidence to show that 
peripheral immune cells have a causative effect on CNS. Grace et al. have reported that 
transplantation of splenocytes from a rat donor with chronic constriction injury that 
displayed higher allodynia to a recipient rat potentiated the recipient’s low 
allodynia(193). Similarly, we can transplant the bone marrow of WT mice into 
TLR2KO or TLR4KO mice and vice versa. If the TLR on epithelial cells are 
responsible for the morphine-induced dysbiosis and tolerance, despite bone marrow 
transplantation from WT mice, the gut microbiota will be resistant to chronic morphine 
treatment. Moreover, the dysbiosis of WT mice, in spite of bone marrow transplantation 
of TLR2KO or TLR4KO mice, will be induced by morphine. However, if the TLR on 
immune cells are responsible for the morphine-induced microbial alteration and 
behavior changes, the dysbiosis will be manifested in TLR2KO and TLR4KO mice 
after bone marrow transplantation of WT mice. The WT with TLR2KO or TLR4KO 
bone marrow transplantation will display attenuated morphine tolerance with less 
dysbiosis.  
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Another model that will allow us to discriminate the cell type that is responsible for 
morphine-induced tolerance is the use of cre-lox mice mediated conditional knockout. 
Conditional TLR deletion on epithelial cells have been generated by breeding floxed 
TLR (TLRfl/fl) with villin-cre (Vil-Cre) mice. If TLR on epithelial cells are responsible 
for morphine-induced dysbiosis and analgesic tolerance, the conditional TLR knockout 
mice will exhibit similar response as conventional TLRKO mice. Moreover, to 
demonstrate whether TLR on immune cells is the primary cause of morphine-induced 
pathological changes in the gut and behavior, the floxed TLR (TLRfl/fl) can be crossed 
with lysosome-cre (lysM-Cre) mice to generate conditional TLR knockout on myeloid 
cells. If TLR on immune cells contributes to morphine-induced dysbiosis and analgesic 
tolerance, the conditional TLR knockout mice will resemble the microbiota profile as 
conventional TLRKO mice. These studies can delineate how peripheral TLR2 and 
TLR4 regulate CNS, thus contributing to morphine analgesic tolerance.  
 
In our studies, we demonstrated that TLR2 and TLR4 are crucial elements to morphine-
induced analgesic tolerance. As previously mentioned, LPS-RS, a TLR4 antagonist, 
prevented both the development of analgesic tolerance and the acquisition and 
maintenance of morphine-induced CPP(90). Simultaneously, HKLM, a TLR2 agonist, 
induced lasting tactile allodynia in mice(95). Therefore, we propose that TLR2 and 
TLR4 antagonists are potential agents to inhibit chronic morphine-induced behavioral 
changes. Small molecule drug screening could be undertaken to identify novel drugs to 
inhibit the activation and expression of TLR2 and TLR4.  
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In our studies, we propose IL-6 as a downstream factor of TLR2 and TLR4 activation 
that can contribute to morphine tolerance. However, our results show only partial 
attenuation of morphine tolerance in the IL-6KO mice. This suggests that other factors 
may be involved in morphine tolerance, including cytokines/chemokines such as IL-
1b, TNFa, CXCL1, IL-10, CXCL12 and other peripheral factors such as complement 
factor 5 receptor (C5aR), tissue plasminogen activator (tPA), neuronal matrix 
metalloproteinase 9 (MMP9), and neuronal nitric oxide 
synthase(80)(82)(83)(84)(85)(86). Studies have confirmed the presence of additional 
peripheral mechanisms affecting morphine tolerance. For example, morphine tolerance 
could be abolished by blockade of peripheral MOR on DRG by methylnaltrexone 
bromide, or blockade of JAK2/STAT3 pathway by regulating miR-375, or activation 
of Mrg3C receptor in DRG(194)(195)(196). Taken together, these studies have 
indicated that peripheral MOR activation plays a crucial role in morphine tolerance, 
and therapeutics targeted at inhibiting peripheral MOR may prolong morphine’s 
efficacy at central analgesic sites.  
 
In our studies, we focused on increasing cytokine levels in CNS in morphine tolerant 
mice. Additionally, many investigators have clearly demonstrated that cytokines and 
chemokines are upregulated by activated microglia and astrocytes and infiltrating 
immune cells(79). Future studies will characterize the role of microglia and astrocytes 
in morphine analgesic tolerance will be determined by detecting Ionized calcium 
binding adaptor molecule 1(Iba1) as a marker of microglia and glial fibrillar acidic 
protein (GFAP) as a marker of astrocyte(197). The morphological changes and 
activities of non-neuronal cells will be determined in morphine-treated GF mice, ABX 
mice, probiotics-treated mice, TLR2KO, TLR4KO and IL6KO mice and their controls. 
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To detect the role of TLR2 and TLR4 on microglia or astrocyte on analgesic tolerance, 
Cx3cr1-cre mice or Aldh1l1-cre mice can be crossed with TLRfl/fl mice to specifically 
delete TLR on microglia or astrocytes(198)(199).  
  
In addition to changes on immune cells, we speculate that alterations on morphine 
concentrations in CNS might contribute to analgesic tolerance. To determine whether 
morphine-induced dysbiosis affects morphine concentrations in CNS, we will 
administer morphine-D3 in naïve and chronic morphine-treated mice. Then the 
concentration of morphine-D3, and its metabolites morphine-D3-6-β-D-glucuronide and 
morphine-D3-3-β-D-glucuronide will be determined in the plasma, CNS and intestinal 
contents by liquid chromatography–mass spectrometry (LC-MS). We hypothesized that 
there will be an accumulation of morphine-D3-6-β-D-glucuronide and morphine-D3-3-
β-D-glucuronide in the mouse intestinal contents and reduced morphine-D3 
concentration in mouse plasma and CNS in chronic morphine-treated mice compared 
to morphine-naïve mice. It is speculated that β-glucuronidase activity is significantly 
decreased due to beneficial bacteria depletion in morphine tolerant mice. Therefore the 
activity and expression of β-glucuronidase will be compared in morphine naïve mice 
and chronic morphine-treated mice.  
 
Both our studies and Taylor et al. demonstrated gut dysbiosis in morphine-treated 
mice(79)(118). However, the fundamental question of how morphine induces gut 
dysbiosis has not been clearly elucidated. Banerjee et al. showed morphine altered the 
cholesterol metabolism, converting cholesterol into coprostanol instead of primary bile 
acids(118). Consequently, less primary and secondary bile acids were detected in the 
intestine(60). Reduced bile acids in the intestine are associated with pathogenic 
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bacterial overgrowth and inflammation(200). Simutaneously, the morphine-induced 
deleterious intestinal environment suppresses the growth of beneficial bacteria with bile 
acid hydrolase (BSH) and β-glucuronidase activity(118). Therefore, imbalance 
between beneficial bacterial and pathogenic bacteria can alter primary and secondary 
bile acids in the gut, thus excerbating morphine-induced dysbiosis. However, the 
precise mechanisms of how morphine induces dysbiosis are not completely understood. 
Whether supplementation of bile acids or bile acid derivatives could attenuate 
morphine-induced dysbiosis and morphine-induced analgesic tolerance needs further 
investigation.  
 
Additionally, we determined that morphine-induced gut dysbiosis regulates 
inflammation, contributing to analgesic tolerance. The immune system keeps a delicate 
balance by eliminating invading pathogens while maintaining self-toleance to 
symbiotic bacteria. The commensal bacteria induce regulatory T cells, regulate SIgA 
synthesis and diversity of antibody repertoires, and thereby promote immunological 
tolerance and preventing immune overreaction(201). Moreover, the gut barrier, mucus, 
and antimicrobial peptides shape and control the composition of enteric 
inhabitants(202). However, morphine-induced gut dysbiosis causes immune 
dysregulation by altering the equilibrium between immune tolerance and immune 
activation. Morphine induced-dysbiosis facilitates bacterial translocation. We 
hypothesize that due to acute morphine-induced immunosuppression(203), the 
translocated bacteria and bacterial components such as LPS, LTA and endotoxin are 
not eliminated properly and thereby heading to induce chronic inflammation. The 
chronic immune activation can  damage tight junction proteins in the gut epithelial cells 
and cause more bacterial translocation and further excerbation of chronic inflammation, 
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contributing to morphine analgesic tolerance. However, detailed mechanistic studies on 
how morphine-induced dysbiosis abrogates immune tolerance warrents studies. 
 
In conclusion, morphine tolerance is a complex phenomenon involving pathways at the 
molecular, cellular and systemic levels. At the molecular level, several mechanisms are 
to be explored: the interaction between OPRM1 and TLR2/4 and their shared 
downstream signaling pathways to elucidate how morphine activates and increases the 
expression of TLR2/4. Furthermore, how inflammatory cytokines contribute to 
morphine tolerance through regulating levels of neurotransmitters, their receptors and 
downstream signaling pathways are also areas of further investigation. At the cellular 
level, which cell type (epithelia, immune cells, microglia or astrocytes) contributes to 
morphine-induced dysbiosis and influences the behavioral changes are important area 
I am interested in. At the systemic level, concentration of morphine and its metabolites 
and other possible mediators (vagus afferents and microbiota metabolites) that 
modulate in gut-brain axis, in addition to cytokines needs to be explored.  
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Figure 4.1 Gene contents inferred from the 16S ribosomal RNA counts based on 
Integrated Microbial Genomes (IMG) database reveal functional contents of mouse gut 
microbiota of Water+Saline and Water+Morphine treatment groups (A) and from 
Water+Morphine and VSL#3+Morphine (B), based on the KEGG functional modules. 
The relative abundance of functional contents was compared between the treated and 
control using Mann-Whitney U-test. 
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CHAPTER 5 
CLINICAL RELEVANCE AND CONCLUSION 
Morphine is a classical painkiller that was isolated from poppy straw of the opium 
poppy in 1803. Currently, opioids (oxycodone, methadone, morphine, hydrocodone 
and fentanyl) are still among top 10 drugs involved in drug overdose deaths(204). The 
“opioid crisis” related with misuse and addiction to opioids still affect public health and 
social and economic welfare. There are growing literature demonstrating gut 
microbiota alteration in substance abuse, including alcohol, tobacco, cocaine, 
hallucinogens (phencyclidine and ketamine), methamphetamine, 3,4-
methylenedioxymethamphetamine (MDMA), morphine, heroin, marijuana(205). 
However, the precise mechanisms how microbiota modulate drug tolerance, 
dependence and addiction have not been clearly delineated. The gut-brain axis paves a 
new path to solve opioid crisis and drug abuse problem. Better understanding of the 
mechanism of microbiota-host interaction can help develop novel therapeutic strategy 
to solve the “opioid crisis”.  
 
Our study provides evidence for the role of the gut-immune-CNS axis in morphine 
analgesic tolerance. Chronic morphine use induces gut dysbiosis and initiates local 
inflammation through TLR2 and TLR4 activation. This results in increased expression 
of pro-inflammatory cytokines, which contributes to morphine tolerance, and acts as a 
feed-forward loop in aggravating dysbiosis, impairing gut integrity, leading to further 
bacterial translocation, thus exacerbating inflammation and sustaining morphine 
tolerance (Fig 5).  
 
In our study, we use VSL#3 probiotics to restore morphine-induced dysbiosis, therefore 
 110 
attenuating tolerance in a rodent model. Our study highlights the missing bacteria 
Bifidobacterium and Lactobacillus in morphine-induced behavior changes, which 
provide a new insight into their role in modulating morphine analgesic tolerance. More 
detailed studies are needed to detect the gut dysbiosis on opioid-dependent humans. 
Our studies in rodents can be used as a backdrop to design future human studies on how 
modulating gut microbiota can be exploited to prolong the efficacy of opioids as 
analgesic agents. 
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Figure 5.1 Schematic diagram shows the role of the gut-immune-brain axis in 
morphine tolerance. Chronic morphine use induces gut dysbiosis and initiates local 
inflammation through TLR2 and TLR4 activation. This results in increased expression 
of pro-inflammatory cytokines, contributes to morphine tolerance, and acts as a feed-
forward loop in aggravating dysbiosis, impairing gut integrity, leading to further 
bacterial translocation, thus exacerbating inflammation and sustaining morphine 
tolerance. 
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